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ABSTRACT  
   
Vitamin D deficiency has been previously associated with a higher Alzheimer’s 
disease (AD) risk, a condition marked by dependent living and severe cognitive 
impairment. AD is histologically defined by the presence of brain amyloid beta (Aβ) 
plaques and neurofibrillary tangles. Ways to enhance Aβ clearance have been examined 
in order to sustain cognition and delay AD onset. In vitro and in vivo studies suggest that 
vitamin D might enhance brain Aβ transportation to the periphery by up-regulating P-
glycoprotein production. The purpose of this study was to examine the effect of vitamin 
D supplementation on plasma Aβ in an older population.   
This study was a parallel-arm, double-blinded, randomized control trial. 
Participants consumed either a vitamin D supplement or placebo once a week for eight 
weeks (n=23). Only vitamin D insufficient (serum total 25-OH, D < 30 ng/mL) people 
were included in the study, and all participants were considered to be cognitively normal 
(MMSE scores > 27). Serum total 25-OH, D and plasma Aβ1-40 measurements were 
recorded before and after the eight-week trial. The plasma Aβ1-40 change was compared 
between the vitamin D group and control group.  
The vitamin D group experienced a 45% greater change in plasma Aβ1-40 than the 
control group. The effect size was 0.228 when controlling for baseline plasma Aβ1-40 
(p=0.045), 0.197 when controlling for baseline plasma Aβ1-40 and baseline physical 
activity (p=0.085), and 0.179 when controlling for baseline plasma Aβ1-40, baseline 
physical activity, and age (p=0.116). In conclusion, vitamin D supplementation might 
increase brain Aβ clearance in humans, but physical activity and age also appear to 
modulate Aβ metabolism.  
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CHAPTER 1 
INTRODUCTION 
Problem 
Approximately thirty-five million people have Alzheimer’s disease (AD), a 
progressive neurodegenerative disorder characterized by substantial cognitive decline 
(Ferri et al., 2005). The global prevalence is projected to increase fourfold by 2050, 
causing economic and societal strain (Brookmeyer, Johnson, Ziegler-Graham, & Arrighi, 
2007). To compound the problem, current AD treatments are only modest in efficacy and 
no cure exists (Wimo et al., 2014). Nonetheless, roughly one third of AD cases might be 
due to modifiable risk factors (Norton, Matthews, Barnes, Yaffe, & Brayne, 2014). 
Hence, there is a need to identify risk factors in order to create primary treatments.  
 The two histological consistencies of AD are neurofibrillary tangles and amyloid-
beta peptide (Aβ) cerebral plaques (Karantzoulis & Galvin, 2011). Aβ is a normal 
byproduct of amyloid precursor protein (APP) metabolism, but will build up in cerebral 
interstitial space if excessively produced or inadequately cleared (Wijesuriya, Bullock, 
Faull, Hladky, & Barrand, 2010). Excessive Aβ accumulation atrophies the brain and 
disrupts cerebral activity (Mattsson et al., 2015). This manifests in severe memory loss 
and further executive function impairment (Karantzoulis & Galvin, 2011).  
Aβ peptides are cleared across the blood-brain barrier (BBB) through two 
transport proteins: lipoprotein receptor-related protein 1 (LRP-1) and P-glycoprotein (P-
gp). An inverse relationship between brain P-gp and Aβ has been observed in human 
post-mortem AD cases. P-gp is encoded by the multidrug resistance protein gene 
(MDR1) and requires the vitamin D receptor (VDR) as a transcription factor. VDRs are 
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abundantly expressed in the central nervous system and are especially saturated within 
the hippocampus (Saeki, Kurose, Tohkin, & Hasegawa, 2008). Being that VDR 
activation increases P-gp expression, those with insufficient vitamin D might not 
proficiently transport Aβ out of the brain. See Figure 1.  
 
Several experimental models confirm vitamin D enhances Aβ transportation out 
of the brain. In human brain microvessel cell lines, 100 nm of calcitriol decreased brain 
Aβ by 25-30% (Durk et al., 2012). In mice, calcitriol increased hippocampal P-gp 
expression and lowered brain Aβ levels by 30% (Durk et al., 2014). Hence, the Aβ 
modulating effects of vitamin D make for a potential lifestyle intervention  
 Although life style factors have been reported to influence AD risk, few trials 
have examined the effects of a lifestyle intervention on Aβ metabolism (Norton et al., 
2014). Lifestyle interventions are valuable because they can be employed early in the 
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disease process. Lifestyle interventions could decrease AD risk by 4.8% and decrease 
Medicare costs by nearly $250 billion, while also being cost-effective complements to 
pharmaceuticals, as the projected drug development cost is $569.3 billion (Scott, 
O'Connor, Link, & Beaulieu, 2014; Sperling et al., 2011).  
Epidemiological data justifies examining vitamin D as a potential therapeutic 
option. A significant association between vitamin D deficiency and dementia has been 
observed in multiple populations (Balion et al., 2012; Littlejohns et al., 2014). Vitamin D 
deficiency has also been associated with faster cognitive decline in several populations 
(Toffanello et al., 2014; Wilson et al., 2014). This is striking because nearly 1 billion 
people worldwide are suspected to have inadequate vitamin D levels (F Holick, 2011).  
Proposed Research 
The objective of this research was to examine the effect of vitamin D 
supplementation on plasma Aβ in healthy adults over the age of 50. The aim was to 
determine whether vitamin D supplementation increases plasma Aβ. No relationship 
between vitamin D supplementation and plasma Aβ was suspected.  
Definition of terms 
Apoptosis: Cell death 
Calcitriol: The biologically active form of vitamin D. 
Expression: The induction of protein production from genetic sequences.  
Hippocampus: A brain structure involved in memory processing.  
Modifiable risk factor: A risk factor for which an individual can amend.  
Post-mortem: After death 
Transcription factor: Proteins that help initiate RNA production from DNA sequences. 
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Abbreviations 
AD: Alzheimer’s disease 
AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxasolepropionic acid receptor 
α7 nAChR:  α7 nicotinic acetylcholine receptor 
APP: Amyloid precursor protein 
Aβ: Amyloid beta  
BBB: Blood-brain barrier 
BDNF: Brain derived neurotrophic factor 
BPSD: Behavioral and psychological symptoms 
CSF: Cerebrospinal fluid 
ER: Endoplasmic reticulum  
HR: Hazard ratio 
LTP: Long-term potentiation  
MCI: Mild Cognitive Impairment 
MMSE: Mini-mental state examination 
MRI: Magnetic resonance imaging 
NCI: Not Cognitively Impaired 
NGF: Nerve growth factor 
NMDAR: N-methyl-d-aspartate-receptor receptor 
PET: Positron emission tomography  
P-gp: P-glycoprotein 
RCT: Randomized control trial 
 
RDA: Recommended Dietary Allowance 
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RR: Relative risk 
Tg: Transgenic 
TrkA: Tyrosine kinase receptor A 
TrkB: Tyrosine kinase receptor B 
VDR: Vitamin D receptor 
WT: Wild type 
Delimitations and Limitations 
 There are several limitations to this study. First, Aβ can bind to various proteins 
in the blood, and other determinants of Aβ continue to be investigated (Costa, Ortiz, & 
Jorquera, 2012). Second, participants were not tested for ApoE4, the allele strongly 
associated with AD (Bennet et al., 2007). Third, participants’ food intake and physical 
activity were collected using surveys, which are prone to substantial measurement error. 
Fourth, overall macronutrient and micronutrient data was not collected. Fifth, the sample 
size was small, categorizing this study as a pilot trial. Finally, results might not be 
generalizable to diabetic or demented individuals outside of the Phoenix metro area of 
Arizona who are taking statins.   
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CHAPTER 2 
LITERATURE REVIEW 
Alzheimer’s Disease (AD) 
Dementia and AD Overview  
Dementia is a category of several types of reversible and irreversible 
neurodegenerative conditions, but AD represents nearly 60% of all dementia cases 
(American Psychiatric & Task Force on, 2000; Van Marum, 2008). Reversible types of 
dementia have identifiable causes (e.g., vitamin B12 deficiency, hypothyroidism, etc.), 
whereas the causes of irreversible dementia continue to be investigated. AD is an 
irreversible type, categorized alongside frontotemporal dementia and lewy body dementia 
(Tripathi & Vibha, 2009). AD is distinguishable from other irreversible forms based on 
two histological findings: plaques composed of amyloid beta peptides (Aβ) and 
intracellular neurofibrillary tangles (Selkoe, 2004). Experimental models suggest plaques 
and tangles disrupt the limbic and cortical system, which manifests in significant memory 
impairment and executive function deficiencies (Karantzoulis & Galvin, 2011). Even 
though there is a need for effective treatments, none have been developed partially 
because the etiological mechanisms are still unclear (Wimo et al., 2014).  
Aβ Overview  
 Aβ gradually accumulates years before AD is detected. When patients express AD 
symptoms, there is already roughly 30-60% less neurons in the hippocampus (Price et al., 
2001). Hence, disrupting Aβ accumulation early in the pathological progression might be 
a prime strategy.  
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Aβ production. Aβ peptides are a normal byproduct of amyloid precursor protein 
(APP) proteolyzation. Although its function is unclear, APP is rapidly produced in large 
quantities. APP is proteolyzed by two exclusive pathways in the trans-Golgi network; one 
produces toxic Aβ and the other produces non-toxic Aβ. The non-toxic Aβ pathway 
includes α- secretase and γ-secretase, whereas the toxic Aβ pathway includes BACE1 and 
γ-secretase (O'Brien & Wong, 2011). 
Toxic Aβ is a derivative of two APP cleavages. First, BACE1 cleaves APP in the 
ectodomain region to produce sAPPβ. Second, γ-secretase cleaves the trasmembrane 
APP-C terminal fragment to generate Aβ1-40 and Aβ1-42. The Aβ1-40 form is produced at a 
higher rate than Aβ1-42, but the more amyloidogeneic form is Aβ1-42. Both isoforms, if not 
degraded, are transferred in vesicles to the extracellular space. Once in the extracellular 
space, Aβ must be cleared via non-enzymatic or enzymatic pathways. (V. W. Chow, 
Mattson, Wong, & Gleichmann, 2010).   
Aβ aggregation occurs even at small concentrations in the neocortex and limbic 
cortex. The peptides amass gradually, starting as 4 kDa monomers, grouping into 
oligomers, and eventually forming the trademark fibrotic plaques. The core of Aβ1-40 and 
Aβ1-42 neurotic plaques consists of internal hydrophobic C-terminals and external 
negatively charged N-terminals (Q. Wang et al., 2011). While the cause of Aβ 
accumulation is not fully understood, evidence points to overproduction and inadequate 
clearance (Mawuenyega et al., 2010; L.-B. Yang et al., 2003).  
There are no useful therapies that sufficiently decrease brain Aβ. A therapy that 
lowers brain Aβ accumulation would be a breakthrough in AD care. Potential therapeutic 
targets include BACE1 or γ-secretase inhibition; however, targeting both these enzymes 
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in mice yielded discouraging results. One study that crossed BACE1−/− mice with 
transgenic (Tg) APP mice produced less Aβ and improved cognition, but consequently 
caused hypomyelination, decreased neurogenesis, vision problems, and seizures (Yan & 
Vassar, 2014).  Likewise, another study that crossed γ-secretase−/− mice with Tg APP 
mice had several adverse outcomes because γ-secretase has nearly 50 substrates, all of 
which have diverse functions, such as gene expression, cell adhesion, ion regulation, and 
neurotrophin signaling (T. Yang, Arslanova, Gu, Augelli-Szafran, & Xia, 2008). 
Therefore, the consequences of BACE1 and γ-secretase inhibition justify the need to 
explore alternative strategies.  
Aβ Clearance. Aβ will accumulate in brain interstitial space if not eliminated by 
enzymatic or non-enzymatic action. Four enzymes predominantly degrade Aβ: matrix 
metallopeptidase 9, glutamate carboxypeptidase II, neprilysin, and insulin-degrading 
enzyme. Three non-enzymatic pathways transport Aβ out of the brain. The first pathway 
transports Aβ from the brain to the cerebrospinal fluid (CSF), which then enters 
perivascular arterial spaces. The second pathway clears Aβ by microglial cell 
phagocytosis. The third pathway transports Aβ across the BBB via active transport 
receptors. BBB dysfunction is of particular interest to scientists studying Aβ clearance 
(Yoon & Jo, 2012).  
The Aβ active transport pathway across the BBB includes two steps. First, Aβ 
enters the endothelial cell LRP1. Second, Aβ is excreted through P-gp, a luminal active 
transport protein encoded by the MDR1 gene (Silverberg et al., 2010). P-gp is 
substantially abundant in the BBB and also exports several substances from the 
neuroparenchyma to the blood (Miller et al., 2000). P-gp is necessary because the BBB 
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only allows for nonpolar molecules to passively diffuse (Wildsmith, Holley, Savage, 
Skerrett, & Landreth, 2013).  
The relationship between Aβ and Pg-p has been extensively examined because of 
the potential for pharmaceutical utility. Lam et al. (2001) first hypothesized that Aβ is a 
substrate for P-gp in vitro. The theory was strengthened when an inverse relationship 
between Aβ deposits and P-gp was quantified in human post-mortem AD cases 
(Vogelgesang et al., 2002). Since then, several in vitro experiments reinforce the theory 
of Lam et al. (2001), suggesting that there is certainly an interaction between P-gp and 
Aβ (Bharate et al., 2015; Kuhnke et al., 2007; Park, Kook, Park, & Mook-Jung, 2014). 
Studies have subsequently examined the relationship between P-gp inhibition and 
brain Aβ levels in mouse models. Cirrito et al. (2005) found that inhibiting P-gp 
expression decreased Aβ clearance. In this study, Tg APP/MDR1−/− mice had more Aβ 
than Tg APP mice that expressed MDR1. When Tg APP/MDR1+/− mice were given a P-
gp inhibitor, the amount of Aβ accumulation predictably increased. Findings from Hartz  
et al. (2010) were similar. Rather than inhibiting P-gp expression, they found that 
prompting the expression of P-gp decreased brain Aβ. These results imply that P-gp is a 
viable therapeutic target to decrease brain Aβ. 
 Indeed, many studies show P-gp up-regulation increases Aβ clearance in mouse 
models and humans. Currently, known P-gp up-regulators include St. John’s wort, 
caffeine, and rifampicin. Tg APP mice that were administered St. John’s wort increased 
P-gp expression, subsequently increasing Aβ clearance (Brenn et al., 2014). Wild type 
(WT) mice that were given both caffeine and rifampicin cleared 20% more Aβ than 
controls, also a result from increased P-gp expression (Qosa, Abuznait, Hill, & 
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Kaddoumi, 2012). Just as rifampicin was beneficial for clearing Aβ in mice, so too was it 
beneficial in humans, as a three-month trial significantly improved cognition (Loeb et al., 
2004). Therefore, therapies that increase P-gp expression might be a viable option to 
delay cognitive impairment.  
Alzheimer’s Disease and Brain Dysfunction  
 AD manifests in severe cognitive impairment because of several interlaced, 
degenerative mechanisms. In AD, synapses fail, cytosolic calcium increases, 
neurotrophin and neurotransmitter utility declines, and mitochondria stop functioning 
(Hirai et al., 2001; Hock, Heese, Hulette, Rosenberg, & Otten, 2000; Pierrot, Ghisdal, 
Caumont, & Octave, 2004; Purves, 2001; H. W. Querfurth & LaFerla, 2010).   
Synapses. A synapse is a gap junction between a neuron and its target cell, the 
site where ions and organic molecules are exchanged. The axonal end of the first neuron 
is called the pre-synapse, and the dendritic end of the second neuron is called the post-
synapse, with the small space in-between is called the synaptic cleft. The small synaptic 
cleft size (3 nm) allows for remarkably fast communication; therefore, transmission is 
sensitive to slight disturbances (Bear, Connors, & Paradiso, 2007, pp. 103-105). In AD, 
interneuron synapses are the types that degenerate (S. W. Scheff & Price, 2003).  
The literature has consistently shown that synaptic failure is a distinct 
consequence of AD. Human brain and AD mouse models demonstrate that synaptic 
failure leads to severe cognitive impairment (DeKosky & Scheff, 1990). In fact, gradual 
degeneration of synapses has been observed many years before AD is clinically 
diagnosed. For example, Scheff et al. (2007) demonstrated that there is an inverse 
relationship between synaptic count and size in individuals with Mild Cognitive 
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Impairment (MCI) (R=0.414; p<0.03), a condition preceding the clinical definition of 
AD. Specifically, those with MCI had 5% larger synaptic volume than not cognitively 
impaired (NCI) individuals (p<0.05). An inverse relationship between synaptic count and 
size suggests that synapses grow larger to compensate for count loss. Not surprisingly, 
there was also a relationship between total hippocampal synapses and MMSE scores 
(r=0.595; p<0.001). Hence, neurodegenerative patterns mirror synaptic morphology.  
Calcium Regulation. Calcium (Ca2+) is ubiquitous in brain physiology. The 
functions of cytosolic Ca2+ include gene expression, neurotransmitter release, memory 
recall, cell survival, and action potential stimulation. Ca2+ homeostasis is crucially 
maintained by many mechanisms to ensure healthy brain physiology. For example, Ca2+ 
can enter the cytosol from the extracellular matrix, endoplasmic reticulum (ER), and 
mitochondria. From the extracellular space, Ca2+ enters the cytosol through activated N-
methyl-d-aspartate receptors (NMDRs), α-amino-3-hydroxy-5-methyl-4-
isoxasolepropionic acid receptors (AMPARs), and voltage gated calcium channels. Once 
in the cytosol, Ca2+ can be stored within the endoplasmic reticulum (ER) and the 
mitochondria. To maintain homeostasis, the ER releases Ca2+ back into the cytosol 
through the membrane channels inositol trisphosphate receptor (IP3R) and ryanodine 
receptor (RyR). Disruption to any of these Ca2+ regulatory mechanisms has deleterious 
effects (Woods & Padmanabhan, 2012).   
Abnormal Ca2+ regulation has been linked to memory loss, mediated by neuronal 
death and Aβ production. Neuron survival and memory depends on a balance between 
cytosolic Ca2+ and mitochondrial Ca2+. High cytosolic Ca2+ forces mitochondrial Ca2+ 
uptake, which in turn opens the permeability transition pore. This opening releases 
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cytochrome c and consequently starts the apoptosis cascade (Giacomello, Drago, Pizzo, 
& Pozzan, 2007). Additionally, high cytosolic Ca2+ induces memory loss independent of 
neuronal apoptosis. Normally, phosphorylation of AMPAR induces long-term 
potentiation (LTP), the mechanism by which memories are formed, but elevated cytosolic 
Ca2+ results in endocytosis of AMPARs (Supnet & Bezprozvanny, 2010). Furthermore, 
elevated cytosolic Ca2+ increases Aβ production. In vitro studies showed elevated 
cytosolic Ca2+ represses α- secretase activity, the first enzyme involved in producing the 
non-amyloidogenic form of Aβ, and increases production of Aβ1-42 (Pierrot et al., 2004). 
Accordingly, stabilizing cytosolic Ca2+ would conceivably improve memory processing 
by protecting neurons and decreasing toxic Aβ levels.  
Neurotransmitters. Neurotransmitters function as interneuronal chemical 
messengers. They are organized into vesicles and released into the synaptic cleft when 
the neuron is depolarized. The organic messengers thereafter bind to post-synapse voltage 
gated ion channels or G proteins (Bear et al., 2007, p. 141). Although there are several 
neurotransmitters, AD scientists are primarily concerned with acetylcholine and 
glutamate.  
Acetylcholine and glutamate are involved in synaptic plasticity and APP 
metabolism. In AD, acetylcholine production is decreased because the basal forebrain 
structures degenerate, the site of the brain that produces acetylcholine (Mesulam, 2004). 
This is problematic because acetylcholine stimulates LTP by binding to the α-7 nicotinic 
acetylcholine receptor and muscarinic type 1 acetylcholine receptor, and binding of the 
muscarinic type 1 acetylcholine receptor also decreases Aβ production by promoting the 
non-amyloidogeneic APP processing pathway (H. Querfurth, 2010). In addition, synaptic 
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plasticity is further strengthened by the action of glutamate. Glutamate acts on NMDARs 
to stimulate cAMP response element binding protein (CREB) production, a necessary 
transcription factor for LTP (Snyder et al., 2005). However, evidence of decreased 
glutamate utility was found in human post-mortem AD brains, which specifically showed 
decreased hippocampal mRNA of NMDAR subunits (Hynd, Scott, & Dodd, 2004). Drug 
developers aim to alter the metabolism or binding affinity of both these neurotransmitters 
(Bond et al., 2012).  
Neurotrophins. Neurotrophins support neuron growth, survival, and repair. AD 
affects mainly two neurotrophins: brain derived neurotrophin factor (BDNF) and nerve 
growth factor (NGF). BDNF binding prompts LTP and sustains the function of 
hippocampal, cortical, cholinergic, and dopaminergic neurons. NGF binding releases 
acetylcholine, activates muscarninic receptors, and limits α-secretase activity. Both 
neurotrophins bind to pan-neurotrophin receptors p75, but BDN binds to tyrosine kinase 
receptor B (TrkB) and NGF binds to tyrosine kinase A (TrkA) (Allen, Watson, & 
Dawbarn, 2011). As such, decreased expression of these neurotrophins or receptors 
would damage neurons and impair memory processing.  
BDNF and NGF expression, as well as its receptors, are decreased in AD mouse 
models and post-mortem cases. In human post-mortem brain preparations, the levels of 
BDNF were much lower than healthy controls (Hock et al., 2000). In mice models, 
exogenous BDFN significantly improved synaptic integrity in the entorhinal cortex and 
dentate gyrus (Nagahara, 2009). Whereas BDNF levels are lower in AD, NGF levels did 
not differ between AD and NCI cases. However, there were 56% less TrkAs in AD brain 
models compared to NCI, reflecting poor NGF utility (Mufson et al., 2000). Increasing 
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the expression of neurotrophins and its receptors theoretically might sustain memory and 
delay neurodegeneration.  
Mitochondria. The mitochondria are responsible for producing ATP. The brain 
uses nearly 25% of the body’s total glucose supply for synaptic transmission, calcium 
homeostasis, and neurotrophin and neurotransmitter activity (Khatri & Man, 2013). 
Mitochondria additionally regulate reduction-oxidation potentials, reactive oxygen 
species (ROS) production, and caspase-mediated programmed cell death (Lin & Beal, 
2006). Hence, damage to mitochondria would have injurious consequences.  
The literature suggests that mitochondrial damage elicits cognitive impairment. 
Much of these observations have been noted using cell-line experiments. In one study, 
mitochondrial enzymes, including cytochrome oxidase, pyruvate dehydrogenase, and α-
ketoglutarate dehydrogenase, were found to be much lower in AD brains compared to 
NCI brains (Reddy & Beal, 2008). In another study, cytoplasmic mitochondrial DNA was 
found to be much higher in AD brains than NCI brains (Hirai et al., 2001). Predictably, 
Swerdlow et al. (2014) showed mitochondrial dysfunction was associated with decreased 
oxygen consumption and a lower NAD +/NADH ratio in cell models. This shift towards 
high NADH slows limits ATP production by slowing down glycolysis. Increased 
expression of COX2, the protein that converts arachidonic acid to prostaglandin H2 to 
mediate cell apoptosis was also observed. Altogether, mitochondrial damage might be 
one mechanism for which cognition is impaired.  
The Effects of Aβ on Brain Physiology  
 Aβ disrupts memory by promoting brain atrophy and dysfunctional cerebral 
activity (Mattsson et al., 2015). Aβ impairs synaptic transmission, Ca2+ homeostasis, 
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neurotransmitter availability, neurotrophin availability, and mitochondrial function (Allen 
et al., 2011; Pagani & Eckert, 2011; Shipton et al., 2011; H. Y. Wang, 2000; Xie, 2004). 
 Aβ and Synapses. Many experimental models demonstrate that Aβ impairs 
synaptic transmission. One way for which Aβ can disrupt synaptic transmission is by 
influencing hyperphosphorylation of microtubule tau protein through glycogen synthase 
kinase 3 activation. Fittingly, inhibiting glycogen synthase kinase 3 reduced 
neurofibrillary tangles and prevented Aβ-induced memory impairment in mice (Shipton 
et al., 2011). Furthermore, Aβ oligomers change synaptic structure. Dendritic spines of 
hippocampal neurons grew extremely thin when exposed to Aβ in cell lines, an 
observation that resembled dendritic structure in mental retardation. Dendritic spin 
density even decreased by 50% only after 24 hours of Aβ exposure (Lacor et al., 2007). 
These results are consistent with previously reported dendritic spinal morphology in AD 
mouse models (Jacobsen et al., 2006).  
 Aβ and Ca2+ Homeostasis. The effect of Aβ on Ca2+ is apparent in the literature. 
Several in vitro experiments have shown that Aβ increases intracellular Ca2+ to an 
excitotoxic level. Aβ activates NMDARs and opens ER calcium channels in hippocampal 
neurons, causing a prolonged Ca2+ influx into the cytosol (Xie, 2004). Additionally, Aβ 
translocated into bilayer membrane models to form calcium channels, consequently 
increasing the amount of Ca2+ influx upon neuron depolarization (Arispe, Rojas, & 
Pollard, 1993). To compound the problem, Aβ prolongs neuron depolarization by 
blocking voltage-gated fast-inactivating potassium currents (Good, Smith, & Murphy, 
1996). Reducing the amount of Aβ would, in theory, restore Ca2+ homeostasis.  
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 Aβ and Neurotransmitters. High brain Aβ levels disrupt acetylcholine and 
glutamate utility. Aβ interacts with acetylcholine and glutamate receptors in vitro. Aβ 
limits acetylcholine uptake in the postsynapse and reuptake in the presynapse by binding 
to the α7 nicotinic acetylcholine receptor (α7 nAChR) (H. Y. Wang, 2000). LTP was 
significantly increased when an α7 nAchR partial agonist was administered to rat 
hippocampal cells (Kroker, Moreth, Kussmaul, Rast, & Rosenbrock, 2013). Findings 
from Snyder et al. (2015) demonstrated that Aβ also disrupts glutamate transmission by 
inducing the endocytosis of NMDARs at the surface of cortical neurons. NMDAR 
endocytosis disturbed CREB signaling, consequently decreasing LTP. When Aβ levels 
were decreased, NMDARs predictably increased at synaptic surface sites. These findings 
suggest Aβ reduction would sustain the ability of acetylcholine and glutamate to bind to 
its respective receptors.  
Aβ and Neurotrophins. Several experimental models show that Aβ disrupts 
neurotrophin utility. Similar to its effects on neurotransmitter receptors, Aβ also binds to 
the receptors of NGF. This is problematic because NGF produces longer dendrites that 
improve synaptic plasticity, and high concentrations of Aβ were found to shorten 
dendrites by acting as an antagonist to p75NTRs (Arevalo, Roldan, Chacon, & 
Rodriguez-Tebar, 2009). Moreover, soluble Aβ decreases BDFN expression and disrupts 
BDNF signaling (Garzon & Fahnestock, 2007). Indeed, an inverse relationship between 
BDNF expression and Aβ count has been observed in mouse AD models (Peng et al., 
2009). These findings might explains why a 23% decrease in mature BDNF was found in 
AD brains (Ferrer et al., 1999). Therefore, Aβ reduction load would conceivably sustain 
the activity of NGF and BDNF.   
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Aβ and Mitochondria. The mitochondria are sensitive to elevated Aβ 
concentrations. Even though the classical view is that extracellular Aβ deposits are the 
most injurious, many recent studies have also shown intracellular Aβ accumulation 
damages the mitochondria. For instance, monomeric and oligomer Aβ have been found to 
translocate within the mitochondrial membranes of AD brains (Pagani & Eckert, 2011). 
In mice, mitochondrial Aβ decreased cytochrome oxidase activity and stimulated reactive 
oxygen species (ROS) production. This fragemented DNA, suppressed dendritic growth, 
and decreased overall mitochondrial function (Manczak et al., 2010). Undeniably, 
subcellular Aβ induces mitochondrial damage, but Aβ deposits stimulate the 
amyloidogenic APP processing pathway, which might be the reason for excessive 
subcellular Aβ accumulation (Reddy et al., 2010). Nevertheless, Aβ unequivocally 
damages mitochondria even though the underlying mechanisms of Aβ secretion and 
formation still are not fully understood.  
Treatments 
 There are no treatments that reverse or prevent AD. Preliminary data suggests 
lifestyle factors might delay cognitive decline, but no large-scale intervention has yielded 
significant results (Norton et al., 2014). Those with AD are treated with pharmaceuticals 
only after diagnosis. The drugs used to treat AD include cholinesterase inhibitors, 
memantine, and several antipsychotics. However, findings show they are modestly 
effective at best, justifying the need to explore alternative strategies (Bond et al., 2012).  
 Cholinesterase Inhibitors. Cholinesterase inhibitors were created to offset 
cholinergic neuron degeneration. Currently, the American Academy of Neurology 
recommends the use of donepezil, rivastigmine, and galantamine to treat mild to 
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moderate AD (Doody et al., 2001). Recommendations have been reinforced by RCTs that 
show cognitive improvements (Kaduszkiewicz, Zimmermann, Beck-Bornholdt, & van 
den Bussche, 2005). Despite donepezil, rivastigmine, and galantamine differing in 
pharmacological properties, the underlying mechanisms are the same. These drugs stop 
the breakdown of acetylcholine in the synaptic cleft by blocking acetylcholinesterase. 
However, the most cholinesterase drugs can do is modify AD symptoms and cannot be 
used as a primary treatment (Di Santo, Prinelli, Adorni, Caltagirone, & Musicco, 2013).   
 Numerous RCTs have examined the effect of the three cholinesterase inhibitors 
on AD patients. A recent meta-analysis examined the efficacy of cholinesterase inhibitors 
on cognition scores in AD using data from 34 RCTs. Findings showed that the effect size 
of donepezil, rivastigmine, and galantamine was .38, .30, and 0.37 respectively (p<.0001) 
(Di Santo et al., 2013). However, cholinesterase inhibitors are not recommended to treat 
MCI because the evidence for efficacy is weak and usage is associated with substantial 
adverse health outcomes. Data from 5149 MCI cases revealed cholinesterase inhibitor 
usage was associated with a significantly higher relative risk (RR) of muscle spasms (RR: 
7.52; 95% CI: 4.34-13.02), headaches (RR: 1.34; 95% CI: 1.05-1.71), gastrointestinal 
problems (RR: 2.10: 95% CI: 1.30-3.39), dizziness (RR: 1.62; 95% CI: 1.36-1.93), and 
insomnia (RR: 1.66; 95% CI: 1.36-2.02) (Russ & Morling, 2012). While cholinesterase 
inhibitors are mildly effective for those already with AD, they cannot be used as a 
preventive treatment.  
 Memantine. Memantine is used to reduce the severity of cognitive impairment. It 
reduces neuron toxicity by acting as an antagonist to NMDARs. This inhibits neuron 
apoptosis by normalizing intracellular Ca2+ levels (Lipton, 2005). Memantine also 
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decreases Aβ by inhibiting the amyloidogenic APP processing pathway (Alley et al., 
2010). In 2003, the USA Food and Drug Administration approved memantine to treat 
moderately to severe AD (McShane, Areosa Sastre, & Minakaran, 2006). Memantine 
recommendations are polarized in the current literature, with some data suggesting they 
are not cost-effective and other data supporting usage (Tampi & van Dyck, 2007). 
 Like cholinesterase inhibitors, many studies have examined the effect of 
memantine on cognitive outcomes. What has been found is that the effects of memantine 
are larger in moderate to severe AD. Memantine usage after six months improved overall 
cognition and daily activity competence; however, in mild to moderate AD, memantine 
usage only improved cognition by 0.99 points on the 70-point Alzheimer’s Disease 
Assessment Scale-cognitive subscale (95% CI: 0.21-1.78; p=0.01) (McShane et al., 
2006). In regards to using memantine as a primary treatment, there are no reliable data 
that suggest memantine decreases cognitive decline in MCI. It is unlikely that there 
would be benefits because the effects of memantine in mild to moderate AD are minimal 
(Karakaya, Fußer, Schröder, & Pantel, 2013). 
 Studies have also evaluated combined dosages of memantine and cholinesterase 
inhibitors. There are limited data that suggests dual-therapy is better. The only evidence 
that it is more effective are drawn from retrospective analyses (Gareri et al., 2014), which 
is limited by small sample size, lack of control group, and selection bias. It is unlikely 
that combined usage would be successful for MCI because both therapies alone are 
modest.  
 Antipsychotic drugs. AD patients exhibit behavioral and psychological 
symptoms (BPSD), including delusions, anxiety, depression, aggression, agitation, and 
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apathy (Alexopoulos et al., 2007). BPSD is considered to be the most influential factor 
for increased caregiver burden (S. Zhang, Guo, Edwards, Yates, & Li, 2014). Therefore, 
to improve quality of life and reduce caregiver burden, several antipsychotic drugs are 
frequently prescribed to AD patients. To treat depression, serotonin reuptake inhibitors 
(SSRIs) are given, but its efficacy is questioned. Data show that SSRIs did not improve 
depression scores in AD patients in comparison to AD patients who received a placebo. 
In fact, caregivers of these AD patients who received the placebo paradoxically 
experienced higher quality of life and better mental health (Banerjee et al., 2011). To 
treat general BPSP, a variety of drug brands are prescribed, such as olanzapine, 
quetiapine, and risperidone. However, these are associated with faster cognitive decline 
than controls in AD patients. After 36 weeks, patients on antipsychotic drugs scored 
worse on the MMSE by 2.4 points than controls (p=0.004) (Vigen et al., 2011). Despite 
the rationale to administer antipsychotic drugs, some data suggest prescriptions should be 
reconsidered.  
 Healthcare clearly lacks worthwhile AD treatments. The effects of cholinesterase 
inhibitors are mild, with the greatest effect seen in mild to moderate AD. The effects of 
memantine are also mild, but more so in those with moderate to severe dementia 
(Karakaya et al., 2013). Even drugs that treat BPSD have promoted a faster cognitive 
decline and increased caregiver burden (Banerjee et al., 2011). Undeniably, there is a 
need to produce successful primary treatments.  
 Lifestyle Interventions. Previous researchers have hypothesized that diet and 
nutrient supplement interventions are protective against AD. Specifically, fatty acid 
supplementation and low-fat, low-glycemic index intervention studies have been 
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conducted. In a 39-subject RCT, AD patients who supplemented omega-3 fatty acid 
combined with lipoic acid experienced less MMSE score decline than did controls 
(p<0.01) (Shinto et al., 2014). Omega-3 fatty acid supplementation might delay cognitive 
decline epigenetically. Examination of 8,000 genes revealed that omega-3 
supplementation up-regulated nine genes and down-regulated 10 genes, many of which 
suspected to be involved in inflammation and neuron survival (Vedin et al., 2012). In 
addition, low saturated fat and low simple sugar intake lowered CSF Aβ1-42 in those with 
NCI, implying that foods high in saturated fat or have a high glycemic index increase Aβ 
production (Bayer-Carter et al., 2011). Nevertheless, a nutrition educational program in 
11 AD centers did not slow down the rate of decline in AD patients when compared to 
AD patients who did not receive education (Salva et al., 2011). Even though there 
appears to be some relationship between diet and AD-related markers, more work is 
needed in order to incorporate successful diet interventions that are generalizable to the 
public.  
Modifiable risk factors 
  Modifying risk factors might delay the onset of AD. Seven modifiable risk factors 
were identified in a 2010 US National Institutes of Health report: diabetes, midlife 
hypertension, midlife obesity, physical inactivity, depression, smoking, and low 
educational attainment, based on data from meta-analyses that investigated the 
association between these modifiable risk factors and AD (Norton et al., 2014). 
Determined based on pooled data from a variety of studies, the summary RR for AD of 
each modifiable risk factor was as followed: 1.46 for diabetes (95% CI: 1.20-1.88), 1.61 
for midlife hypertension (95% CI: 1.16-2.24), 1.60 for midlife obesity (1.34-1.92), 1.82 
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for physical inactivity (95% CI: 1.19-2.78), 1.65 for depression (95% CI: 1.42-1.92), 1.59 
for smoking (95% CI: 1.15-2.20), and 1.59 for low educational attainment (95% CI: 1.35-
1.86) (Barnes & Yaffe, 2011; Cheng, Huang, Deng, & Wang, 2012; Gao et al., 2013; 
Hamer & Chida, 2009; Peters et al., 2008; TakkoucheéI, 2006). According to estimated 
population-attributable risks, modifiable risk factors make up 9.6 million of 33.9 million 
AD cases. AD would decrease by 8-15% if each risk factor decreased by 10-20% per 
decade (Norton et al., 2014). With such a large percentage of AD attributable to 
modifiable risk factors, further research exploring other potential risk factors should be 
considered.  
Diagnostics 
 According to the National Institute of Neurological Disorders and Stroke 
(NINDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA), AD 
is diagnosed when criteria for dementia are met, symptoms worsen over months to years, 
and psychological batteries indicate amnestic and nonamnestic deficits. Diagnostic 
certainty is increased when combining CSF samples, structural magnetic resonance 
imaging (sMRI), functional MRI (fMRI), and positron emission tomography (PET). 
These tools not only reflect Aβ and tau pathology, but also show structural differences 
and real-time cerebral activity disruption. Still, confirmation of AD can only be made 
post-mortem by the identification of plaques and tangles (McKhann et al., 2011).  
 Physicians assess Aβ and tau pathology using CSF samples and PET scans. 
Concentrations of Aβ and tau are different in living AD patients compared to cognitively 
normal people. For instance, levels of CSF Aβ1-42 and Aβ1-40 are lower than cognitively 
normal controls, and hyperphosphorylated tau levels are much higher in living AD 
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patients (Mattsson et al., 2009). In combination, PET scans also differentiate between AD 
and NCI cases. An individual is classified as Aβ positive if a high amount of radiolabeled 
F 18-florbetapir-P binds to brain Aβ (Klunk et al., 2004). However, PET tracers are still 
being investigated to quantify tau (W. Zhang et al., 2011).  
 Physicians additionally assess structural and cerebral activity irregularities using 
several imaging tools, including PET, fMRI, and sMRI. Brain glucose utilization 
decreases in AD, measured by PET. Overall brain blood flow also decreases in AD, 
measured by functional MRI (fMRI). Findings from PET and fMRI can be supplemented 
with structural MRI (sMRI), a scan that quantifies the severity of brain atrophy 
(Wurtman, 2014). Altogether, CSF, sMRI, fMRI, and PET scans improve diagnostic 
certainty, but the expensive and invasive nature do not allow for large-scale screening.  
Needs 
 Costs. Almost $226 billion will be spent on AD treatment in 2015, and 68% of 
such costs are coming from Medicare and Medicaid (Alzheimer’s, 2015). The societal 
cost burden is similar to that of cancer or heart disease (Hurd, Martorell, Delavande, 
Mullen, & Langa, 2013). By 2050, it could cost nearly $1 trillion to cover the projected 
13.5 million diagnosed AD cases (Alzheimer’s, 2015). Delaying the onset of AD by 5 
years would not only decrease Medicare costs by 25%, but total AD costs by 34% 
(Sperling et al., 2011). 
 Much of the costs for AD come from diagnosing and monitoring disease 
progression. Psychological examinations cost roughly $860; PET and MRI cost nearly 
$3,130; and a comprehensive panel consisting of CSF biomarkers, imaging, and 
psychological examination costs about $4,470 (Wimo et al., 2013). However, 
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psychological batteries might not accurately identify those in the early stages of AD. 
Even the ADAS-Cog, considered by the field to be the gold standard for AD diagnosis, 
has produced false-negatives in those with mild symptoms (Hobart et al., 2013). Hence, 
there is a need to develop more accurate and cost-effective diagnostic tools that can be 
used to detect early pathological changes and monitor treatments.  
 Peripheral biomarkers. No peripheral biomarkers are available to diagnose or 
track AD in living patients. Identifying peripheral biomarker would be a landmark in the 
field. The non-invasive nature of peripheral biomarkers would allow for early diagnosis 
in a cost-effective manner (Hampel et al., 2010).   
 Developing a blood-based biomarker is challenging. One reason is that the 
temporal association between Aβ plaques or neurofibrillary tangles and AD onset is 
unclear (Reddy, 2011). Another reason is that the cause of interstitial Aβ accumulation is 
debated. Both inadequate clearance and overproduction influence interstitial Aβ 
accumulation, but there is no clear consensus for which method is more influential. (Y. J. 
Wang, Zhou, & Zhou, 2006). Because of such challenges, no diagnostic cut-offs have 
been established.  
 Plasma Aβ as a Possible Biomarker. Plasma Aβ has been systematically 
examined because of its potential diagnostic and prognostic utility. Measuring plasma Aβ 
is justified because most interventions wish to alter Aβ metabolism and the assay is 
relatively inexpensive and commercially available. A recent meta-analysis conducted by 
Koyama et al. (2012) analyzed whether change in plasma Aβ levels over time predicted 
AD incidence. RR was determined comparing bottom and top quartiles of data from 13 
prospective studies with 10,303 participants. No relationship between Aβ1-42 and onset of 
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AD was observed (summary RR from nine studies: 1.01; 95% CI: 0.48-2.11; p=0.99), 
whereas those in the lowest quartile for plasma Aβ1-40 were at a borderline significantly 
higher AD risk (summary RR from seven studies: 1.66; 95% CI: 0.98-2.83; p=0.06). 
Notably, those in the lowest Aβ42:40 quartile were at a 1.60 times higher AD risk (95% 
CI: 1.04-2.46; p=0.03). Significant heterogeneity, however, exists amongst the examined 
studied and could be due to different assay methodology and blood collection protocols.  
 Plasma Aβ and AD risk was also assessed by Chouraki et al. (2014) using the 
Framingham Study cohort. In total, 2189 NCI participants were followed for 10 years 
after having plasma Aβ measured at baseline. This is one of the larger sample sizes used 
to assess plasma Aβ, and the single-center nature of the study eliminates the factors that 
influenced heterogeneity in prior meta-analyses (e.g., assay variability, blood collection 
differences, etc.). Higher Aβ1-42 at baseline was associated with a lower AD risk (HR per 
one SD increase in plasma Aβ1-42: 0.79; 95% CI: 0.69-0.90; p>0.001). Likewise, higher 
Aβ42:40 was associated with a lower AD risk (HR per one SD increase in Aβ42:40: 0.85; 
95% CI: 0.73-0.98; p<0.012). However, no significant association for Aβ1-40 and AD was 
observed. In addition, the investigators of this study updated the meta-analysis of 
Koyama et al. (2012) by adding data from the Framingham Study cohort and unpublished 
results. Those in the lowest plasma Aβ42:40 quartile had a 1.53 greater AD risk than those 
in the highest quartile (95% CI: 1.09-2.51; p=0.014), while the association of plasma Aβ1-
42 and Aβ1-40 with AD remained insignificant.  
 Studies have examined the association of plasma Aβ1-40 and lifestyle 
modifications. One cross-sectional study assessed the relationship between physical 
activity levels and plasma Aβ1-42 and Aβ1-40. Findings suggest that higher levels of 
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physical activity might lower the Aβ42:40 ratio (Brown et al., 2013). Another study 
examined the effect of high-dosage B-vitamin supplementation on plasma Aβ1-40. 
Participants receiving B-vitamin supplements over two years had a 16% lower mean 
plasma Aβ1-40 change than did controls, albeit results did not achieve traditional 
significance (p=0.08) (Flicker et al., 2008). The third study tested high-dosage curcumin 
supplementation on plasma Aβ1-40. Those receiving curcumin significantly lowered 
plasma Aβ1-40 after four weeks of treatment (p<0.01) (DiSilvestro, Joseph, Zhao, & 
Bomser, 2012). Such findings are inconsistent with the literature that suggests low Aβ 
increases AD risk (Chouraki et al., 2014).  
 Voids. The National Alzheimer’s Project Act of 2011 reflects the urgency to treat 
AD. The field aims to provide effective treatments by 2025, according to the National 
Plan to Address Alzheimer’s Disease (Naylor et al., 2012). Epidemiological evidence 
suggests low serum vitamin D increases AD risk (Littlejohns et al., 2014). Hence, 
examining the relationship between vitamin D status and plasma Aβ is merited.  
Vitamin D and Alzheimer’s Disease 
Overview 
 Vitamin D is a fat-soluble derivative of cholesterol and a secosteroid. It is 
necessary for humans because its flexible chemical conformational binds to a variety of 
proteins (Gropper & Smith, 2008, p. 392). Vitamin D is widely recognized for its role in 
bone metabolism, but its non-skeletal benefits have become a recent focus in the 
literature (Fortmann et al., 2013).  
 Sources. The Recommend Dietary Allowance (RDA) for 51-70 year olds and 
those greater than 70 year olds is 600 IU and 800 IU respectively. The RDA was 
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established in order to reflect healthy bone metabolism (Del Valle, Yaktine, Taylor, & 
Ross, 2011). Dense amounts of vitamin D are found in animal products, including dairy 
products, fish, and liver. Other food products, such as milk, yogurt, cheese, margarine, 
and some orange juices, are even fortified with vitamin D in the US. The main form of 
vitamin D found in animal products is cholecalciferol, and the form found in plants is 
ergocalciferol. Both dietary ergocalciferol and cholecalciferol are absorbed into the 
intestinal cell with a micelle and released into the lymphatic system bound to 
chylomicrons, eventually entering the bloodstream. In addition to diet, vitamin D can be 
attained through sun exposure. Upon sun UVB exposure, skin-synthesized 7-
dehydrocholeterol is converted to precholecalciferol, where UVB photons open the B 
ring and cause a volatile conformation. Precholecalciferol isomerizes to cholecalciferol 
after roughly three days to a more stable form, which in turn enters the bloodstream 
(Gropper & Smith, 2008, pp. 392-393). 
 Metabolism. Cholecalciferol is the predominant form of circulating vitamin D 
and must be hydroxylated twice in order to become biologically active. The first 
hydroxylation occurs in the liver, where cholecalciferol is converted to calcidiol (25-OH, 
D3) by the enzyme 25-hydroxylase. Thereafter, calcidiol circulates in the blood stream 
tightly bound to vitamin D binding protein (DBP), with a half-life of 10 days to three 
weeks. Because of the long half-life, serum total 25-OH, D is used to assess vitamin D 
sufficiency. The second hydroxylation occurs in the kidney, where calcidiol is converted 
to its active form, 1, 25-OH, D3 (calcitriol) by 1-hydroxylase (Gropper & Smith, 2008, 
pp. 394-395). Interestingly, although 1-hydroxylase is found primarily in renal tissue, the 
enzyme is also saturated in neurons and glial cells of the hippocampus, basal forebrain, 
  28 
hypothalamus, prefrontal cortex, and cingulate gyrus (Eyles, Smith, Kinobe, Hewison, & 
McGrath, 2005). Upon reaching its target tissue, calcitriol is released from DBP and 
enters the cell through a vitamin D receptor (VDR). VDRs are not only abundantly 
expressed in the intestine, kidney, and skin, but also in the central nervous system 
(Haussler et al., 2008). 
 Function.  Calcitriol is estimated to be a transcription factor for nearly 3.5% of all 
genes (Dong et al., 2012). It acts on nuclear VDR to induce a conformational change that 
starts the transcription cascade. The calcitriol-VDR-bound dimer forms a heterodimeric 
complex, consisting of retinoic acid or retinoid x receptor, which binds to the vitamin d 
response element (VDRE) on the promoter region of DNA. Additional comodulator 
proteins bind to the heterodimeric complex on VDRE, connecting more transcriptional 
cofactors (e.g., SRC family proteins and NCoA-62) with RNA polymerase II 
(MacDonald, Baudino, Tokumaru, Dowd, & Zhang, 2001). For this reason, limited 
circulating vitamin D would reduce transcription of several genes.  
Low Vitamin D Prevalence 
 Over 1 billion people in the world are estimated to have insufficient vitamin D 
levels (serum total 25-OH, D < 30 ng/mL) (F Holick, 2011). Even those living in lower 
latitudes, where sun exposure is easily attainable, experience insufficiency. In a study 
conducted in a South Florida population, 38% and 40% of men and women had serum 
total 25-OH, D below 20 ng/mL (Tangpricha, 2007). Insufficiency is especially prevalent 
in older populations. According to the National Health and Nutrition Examination Survey 
(NHANES), 27% of men and 35% of women over 50 have insufficient vitamin D levels. 
In a review of 42 studies, the amount of vitamin D insufficient elderly individuals ranged 
  29 
between 40-100% (Barnard & Colón-Emeric, 2010). This is not surprising because the 
elderly synthesize 75% less cholecalciferol than younger adults (Holick, Matsuoka, & 
Wortsman, 1989).  
Molecular Plausibility for Vitamin D and AD  
 In addition to its potential for a lifestyle intervention, vitamin D metabolism could 
also be used as a way to identify pharmaceutical targets that might modulate AD 
pathology. For example, VDRE is a human multidrug resistance protein 1 (MDR1) 
promoter, the gene encoding the Aβ-clearing, active transporter P-glycoprotein. This has 
been shown using a variety of experimental models. In caco-2 cells, calcitriol induced 
MDR1 expression via VDR activation (Saeki et al., 2008). These results were consistent 
with studies that showed activated VDR increases MDR1 expression in rat kidney, rat 
liver, mouse liver, and mouse brain (E. C. Chow, Durk, Cummins, & Pang, 2011; Edwin 
CY Chow, Sun, Khan, Groothuis, & Pang, 2010). In Tg APP mice, calcitriol even 
increased hippomcampal P-gp by 250% (p<0.05) (Durk et al., 2012). Vitamin D 
metabolism shows that targeting VDR would yield more P-gp and, in theory, protect 
against Aβ accumulation.  
 Indeed, activating VDR using calcitriol increases Aβ clearance in experimental 
models. The Aβ clearance rate increased in human brain cells by 30% when exposed to 
calcitriol for three days (p<0.05). In Tg APP mice at the plaque-phase, calcitriol 
decreased soluble Aβ levels by 25-30%, with the highest reductions in the hippocampus 
and cortex (p<0.05) (Durk et al., 2014). These data suggests a noteworthy link between 
vitamin D and Aβ clearance that is mediated by VDR activation.  
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Serum Vitamin D and Cognition 
 There is an association between vitamin D status and cognition. Cross-sectional, 
prospective, and intervention studies all suggest optimal vitamin D sustains cognition.  
Cross-sectional. A strong association between serum total 25-OH, D and 
cognitive impairment was found in French, Italian, US, and English populations. In a 
French 95-participant sample, those with serum total 25-OH, D between 4-16 ng/mL 
were more likely to be cognitively impaired than those with serum total 25-OH, D 
between 32-78 ng/mL (OR: 59.64; 95% CI: 4.62-533.28) (C Annweiler et al., 2012). In 
an Italian representative sample, those with serum total 25-OH, D below 10 mg/mL had a 
four-fold increased risk of cognitive impairment than those over 30 ng/mL (95% CI: 
1.37-9.90) (Llewellyn, Lang, Langa, & Melzer, 2010). Specific to US community-
dwelling residents, those with higher serum total 25-OH, D were more likely to have 
higher MMSE scores (β coefficient = 0.05; p= 0.05) (Buell et al., 2009). Risks for US 
citizens are similar to English citizens. English citizens with serum total 25-OH, D below 
10 ng/mL had nearly a three-fold increased risk of cognitive impairment than those above 
30 ng/mL (95% CI: 1.48-5.00) (Llewellyn, Langa, & Lang, 2009). These findings suggest 
that sufficient vitamin D status slows cognitive impairment.  
Prospective. The relationship between serum 25-OH, D and cognitive decline has 
also been examined over time. Wilson et al. (2014) most recently analyzed this concept, 
enrolling 2,777 US community-dwelling subjects who were 70-79 years old and followed 
for an average of four years. Cognition was quantified using the 100-point Modified 
Mini-Mental State Examination. At follow-up, subjects with serum total 25-OH, D 
between 20 and 29 ng/mL experienced a four times greater cognitive decline than did 
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those with serum total 25-OH, D greater than or equal to 30 ng/mL (p=0.05). Findings 
from Llewellyn et al. (2010) were similar. Italian women with serum vitamin D less than 
10 ng/mL were 60% more likely to have lower MMSE scores than those with serum 
vitamin D greater than 30 ng/mL (95% CI: 1.19-2.00; p<0.05). Also in alignment, 
findings from Slinin et al. (2012) demonstrated that US community-dwelling women with 
vitamin D less than 30 ng/mL were more likely to score worse on the MMSE after four 
years than those over 30 ng/mL (p for trend<0.053). Similarly, Toffanello et al. (2014) 
concluded that those with serum vitamin D less than 20 ng/mL were 36% more likely to 
score worse on the MMSE after four years than those over 30 ng/mL (95% CI: 1.14-1.62; 
p<0.001). Therefore, to imply causality, more randomized control trials are certainly 
justified. 
Interventional. Only a few studies have examined the effect of vitamin D 
supplementation on cognition. One study evaluated the influence of vitamin D 
supplementation on a variety of cognitive domains. Forty-four subjects were assigned to 
a vitamin D or placebo group, and cognition was tested after 16 months of 
supplementation. The supplementation prescriptions varied in dosage according to the 
patient’s physician recommendation (i.e., 800 IU or 100,000 IU month). Nevertheless, 
those receiving vitamin D supplements scored better on the MMSE, Cognitive 
Assessment Battery, and Front Assessment Battery after 16 months (p<0.05) (Cédric 
Annweiler, Bruno Fantino, et al., 2012). Another study showed that an 8-40 week 
supplementation period of cholecalciferol (9000 IUs) did not have a significant effect on 
cognition in 82 participants (Corless et al., 1987). However, much of the resources 
available today were not available then. Today, evidence-based vitamin D 
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supplementation trials have been established, cognitive exams are more robust, and 
vitamin D assays have improved (Hsieh, Schubert, Hoon, Mioshi, & Hodges, 2013; 
Kennel, Drake, & Hurley, 2010; Meunier, Montérémal, Faure, & Ducros, 2015). As such, 
caution needs to be taken when interpreting these interventional results.   
Serum Vitamin D and AD Risk 
 Consistent with studies that suggest adequate vitamin D status sustains cognition, 
vitamin deficiency is also associated with a considerably higher AD risk. Recent 
evidence from a US population-based study conducted by Littlejohns et al. (2014) 
demonstrated that there is a significant association between vitamin D deficiency and 
AD. In total, 1547 dementia-free participants were analyzed after being followed for a 
mean of 5.6 years. Participants with serum total 25-OH, D less than 10 ng/mL had a 
122% higher risk of developing AD than those greater than or equal to 20 ng/mL (95% 
CI: 1.02-4.83). In the same population, for each SD increase in serum total 25-OH, D, 
AD risk decreased by 20% (95 % CI: 0.65-0.99). Moreover, pooled data from six cross-
sectional and case-control studies demonstrated that AD patients have significantly lower 
serum total 25-OH, D than NCI individuals (Balion et al., 2012). Altogether, these imply 
that vitamin D could be a pivotal factor in AD.  
Vitamin D Attainment and AD Risk 
 How vitamin D is attained (i.e., sun exposure or dietary intake) and whether it is 
associated with AD has also been examined. One study assessed vitamin D intake with a 
21-item food frequency question and a sun exposure question, then evaluated its 
association with AD after 7 years. Those in the lowest quintile versus the highest quintile 
of vitamin D intake had a 77% greater chance of developing AD (95% CI: 0.08-0.69). In 
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the same way, the lowest quintile of low sun exposure had a 45% greater chance of 
developing AD (95% CI: 0.24-0.85) (Cédric Annweiler, Yves Rolland, et al., 2012). 
Another study compared diet patterns with AD brain imaging markers. Higher intake of 
vitamin D was associated with increased brain glucose utilization, decreased brain 
atrophy, and lower Aβ accumulation (Berti et al., 2014). Both limited dietary vitamin D 
intake and sun exposure could progress AD.  
Summary 
Current State of AD and Vitamin D Literature 
 In AD, excessive brain Aβ accumulation manifests in severe cognitive 
dysfunction, which is partially mediated by brain atrophy and impaired cerebral activity 
(Mattsson et al., 2015). Even though Aβ is a natural byproduct of APP metabolism, it 
must be cleared or degraded (V. W. Chow et al., 2010). One way by which Aβ is cleared 
is through transportation across the BBB via P-gp. Indeed, evidence from in vitro and in 
vivo studies revealed that P-gp clears Aβ from the brain to the blood (Kuhnke et al., 
2007; Lam et al., 2001). P-gp is coded by the MDR1 gene and requires VDR as a 
transcription factor. Several studies demonstrated that calcitriol increased P-gp 
expression and subsequently the rate of Aβ clearance (E. C. Chow et al., 2011; Durk et 
al., 2012). Such findings might explain why low serum total 25-OH, D was associated 
with greater cognitive impairment and AD risk.  
Vitamin D and AD Voids 
 Little is known about the effect of vitamin D on AD-related markers. Recent 
evidence suggests that vitamin D improves cognition, but no study has examined the 
effect of vitamin D supplementation on outcome measurements that are not cognitive 
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outcomes (Cédric Annweiler, Bruno Fantino, et al., 2012). Furthermore, the field 
critically lacks robust peripheral biomarkers. Peripheral biomarkers would be a 
momentous breakthrough in AD care because they are non-invasive and relatively 
inexpensive (Hampel et al., 2010). One potential peripheral biomarker is plasma Aβ. 
Both curcumin and B-vitamin supplementation lowered plasma Aβ, and one cross-
sectional analysis confirmed that physical activity was associated with lower plasma Aβ 
(DiSilvestro et al., 2012; Flicker et al., 2008). However, these findings contradict large-
scale epidemiological data that suggest low plasma Aβ at baseline increases AD risk 
(Chouraki et al., 2014). The reason for the inconsistent findings could be because 
curcumin and B-vitamin supplementation decreased Aβ production, a pathway that does 
not directly influence Aβ transportation to the periphery. Another problem AD 
researchers have encountered is that it is unknown whether Aβ accumulation is a result of 
overproduction, inadequate clearance, or a combination of both (Mawuenyega et al., 
2010; L.-B. Yang et al., 2003). Altogether, these voids need to be addressed in order to 
develop successful AD therapies.  
Addressing Voids 
 More rigorous RCTs are needed to examine whether vitamin D modulates AD 
pathology. Since some studies have found AD pathology to begin years before symptoms 
manifest, RCTs that use non-psychological measures are needed (Morris, 2005). 
Assessing the effect of vitamin D supplementation on plasma Aβ in humans addresses 
several voids, including how vitamin D modulates AD pathology and what determinants 
for plasma Aβ exist. As a result of more research, the field might progress towards 
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establishing better and cost-effective treatment strategies, ultimately meeting the 
treatment demand for the growing disease prevalence.  
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CHAPTER 3 
METHODS 
Participants and Study Design 
Participant Selection 
 The protocol was approved by the Arizona State University Institutional Review 
Board (Appendix A). Participants were eligible to participate if at least 50 years old and 
vitamin D insufficient (serum total 25-OH, D <30 ng/mL). Participants were excluded if 
diabetes, kidney disease, liver disease, or blood disorders were reported, or excluded if 
cognitive impairment was measured. Diabetes has been associated with aberrant plasma 
Aβ levels (Fishel et al., 2005). Kidney and liver disease impair vitamin D conversion to 
its active form (Gropper & Smith, 2008, p. 395). Blood disorders could alter plasma Aβ 
levels (Ghiso et al., 2004). The intention was to include healthy, older subjects and to 
eliminate known confounding variables of plasma Aβ.  
Recruitment 
 Sites. Participants were recruited through retirement communities (Friendship 
Village and Beatitudes), Arizona State University (ASU), and email listservs of ASU, 
New Frontier, and the Arizona Academy of Nutrition and Dietetics. A poster was placed 
inside the fitness area of Friendship Village, and the investigator spoke at a monthly town 
hall meeting at Beatitudes.   
 Screening. The screening process involved two steps. First, the screening survey 
was administered to interested volunteers in order to assess diabetes, kidney disease, 
statin usage, and blood disorders (Appendix B). Volunteers could fill out the screening 
survey in-person or online at surveymonkey.com. Interested volunteers at Friendship 
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Village and Beatitudes were able to request a screening survey from an employee to 
return back to the same employee. The employee informed the investigator when 
screening surveys were ready for pick-up. Second, if the volunteer passed initial 
screening, a blood draw was scheduled at Friendship Village, Beatitudes, or the Arizona 
Biomedical Collaborative (ABC) lab of downtown Phoenix to assess serum total 25-OH, 
D levels.  
 Enrollment. A total of 152 people completed the screening questionnaire. At the 
start of recruiting, only people 65 years of age or older were eligible for participation; 
however, the age minimum was lowered to 50 years of age or older because recruiting 
was not robust. Out of 152 volunteers, 73 passed initial screening and were scheduled for 
the second screening, a fasting blood draw. After completing a fasting blood, 24 people 
qualified and were enrolled. One participant dropped before the trial began per a 
physician recommendation. A total of 23 started and completed the study. Four 
participants were removed from analysis due to missing data points. As such, 19 
participants were included in analysis. 
Design 
 This study was an eight-week, parallel-arm RCT. Twenty-four subjects were 
randomly assigned to either a vitamin D supplement group or placebo group. Participants 
were matched based on age, BMI, and baseline serum total 25-OH, D. Serum total 25-
OH, D, plasma Aβ1-40, vitamin D intake (IUs/d), and physical activity (METS/week) were 
measured at baseline and follow-up. The main outcome measurement was plasma Aβ1-40 
change.  
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Sample Size 
A sample size of 601 per group was calculated using the Hedwig Harvard Sample 
Size Calculator. Significance was set at 0.05 (two-sided) and power was set at 0.8. The 
sample size was calculated using a previous curcumin supplementation trial and B-
vitamin supplementation trial that used plasma Aβ as an outcome measurement 
(DiSilvestro et al., 2012; Flicker et al., 2008). These two studies aimed to decrease 
plasma Aβ levels by modulating Aβ production. Due to difficulty recruiting and the 
exploratory nature of this study, the sample size in this study was 24 (n=12 per group). 
Based on these two previous studies, the plasma Aβ1-40 change was suspected to be 17.2 
+ 11.1 pg/ml higher in the vitamin D group compared to the control group after the trial. 
See Appendix C.  
Protocol and Procedures 
 Subjects participated in this trial for approximately eight weeks. Subjects met 
with the investigator three times. The first visit was step two in the screening process, 
where serum total 25-OH, D and baseline plasma Aβ were measured. The purpose of the 
second visit was to collect vitamin D intake and physical activity data, disperse 
supplements, and review instructions. The purpose of the third visit was to measure 
follow-up serum total 25-OH, D and plasma Aβ after the supplementation period 
concluded. See Appendix D.  
Visit 1 
 Participants who passed the initial screening were scheduled for a fasting blood 
draw at Friendship Village, Beatitudes, or the ABC lab. Participants gave written consent 
(Appendix E), filled out a brief health-history questionnaire (Appendix F), and were 
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administered the Mini-Mental State Examination (MMSE) (Appendix G) before the 
blood draw. The MMSE is the most common tool used to assess incidence of cognitive 
impairment (Strauss, Sherman, & Spreen, 2006). The brief health-history questionnaire 
confirmed medicine and supplement usage and allowed participants to express additional 
health concerns. A trained phlebotomist or Registered Nurse performed the blood draw. 
Participants were informed of eligibility within 7-10 days (i.e., serum total 25-OH, D < 
30 ng/mL). Blood samples and data were stored in the ABC lab.  
Visit 2 
 Eligible participants were asked to schedule a second visit at Friendship Village, 
Beatitudes, or the ABC lab. Participants were randomized to either the vitamin D group 
or placebo group. Eight supplements were placed in a brown paper bag, identified by ID 
number, and given to participants. This was paper-clipped to a manila folder that 
included a copy of the consent form, supplement instructions, and a calendar. Participants 
also completed the Brief Vitamin D Questionnaire (BVDQ) (Appendix H) and 
Community Health Activities Model Program for Seniors questionnaire (CHAMPS) 
(Appendix I). Both questionnaires were self-administered. The BVDQ reflected intake 
over the last three months. The CHAMPS questionnaire reflected physical activity over 
the last four weeks. The investigator verbally explained how to complete both 
questionnaires. Participants were also reminded once during the eight-week trial to take 
the supplement once a week.   
Visit 3 
Participants were scheduled for a final fasting blood draw at Friendship Village, 
Beatitudes, or the ABC lab roughly one week after supplementation period ended. The 
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BVDQ and CHAMPS were completed once more. Participant were given a $25 Target 
gift card after the blood draw, thus concluding subject participation.  
Measurements 
Survey 
Vitamin D intake and physical activity data were collected via self-administered 
surveys. Vitamin D intake (IUs/day) was quantified using the BVDQ. The BVDQ was 
validated against a three-day food record, the Block Health History and Habits 
Questionnaire 1998 (BHHHQ98), and serum total 25-OH, D. Participants in the 
validation study were postmenopausal women, with a mean age of 63.9 + 7.8 years. The 
tool correlated mildly to the three-day food record (r=0.43; p<0.001) and BHHHQ98 
(R=0.51; p<0.001), but did not correlate to serum total 25-OH-D (p>0.05) (Hacker-
Thompson, Schloetter, & Sellmeyer, 2012). Physical activity was quantified using the 
CHAMPS questionnaire. A randomized control trial was used to determine whether 
CHAMPS could quantify changes in METs/week and frequency of activities as a result 
from an exercise trial. The intraclass correlation (ICC) for moderate and greater 
METs/week was 0.67 and 0.66 respectively after six months. METs/week and frequency 
were significantly correlated for moderate activities (R=0.73; p<0.05) and all activities 
(R=0.55; p<0.05). At the end of the trial, those in the exercise group increased 
METs/week by 687 (p<0.0001). Participants were older (mean=74 years; SD=6), and 
64% of the sample were females (Stewart et al., 2001).  
Blood-based 
Serum vitamin D and plasma Aβ were analyzed. About 10 mL of blood was 
drawn into a serum separator tube (red top) for vitamin D analysis, and about 4 mL of 
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blood was drawn into a sodium heparin tube (green-top) for plasma Aβ analysis. All 
blood samples were centrifuged for 15 minutes at 3000 rpm within four to six hours after 
venipuncture. Immediately after centrifuging, one mL of serum was sent to Sonora Quest 
in a transport tube for total 25-OH, D analysis. Sonora Quest uses LC-MS/MS 
technology and examines both 25-OH, D2 and 25-OH, D3. Additionally, 0.495 mL of 
plasma was immediately aliquoted into pyrogen/endoxin-free tubes, treated with 0.005 
mL of pefabloc (protease inhibitor), and frozen at -80°C. Plasma Aβ1-40 was analyzed in 
the ABC lab using a commercially available assay according to the manufacture protocol 
(Aβ40 Human ELISA Kit; Invitrogen; Appendix J). Samples were run in duplicates and 
diluted two-fold. Dilutions were determined empirically. Samples were read on the 
Biotek H1 Synergy Monochromatic Plate Reader. A four parameter logistic curve was 
generated for the standard curve.  
Compliance 
Compliance was measured using self-reported data. Participants tracked 
supplement consumption using a calendar given to them. Supplements were to be taken 
once a week for eight weeks, and participants were to mark which day of the week the 
supplement was consumed. Calendars were returned at the final visit. Participants who 
lost the calendar were asked how many pills remained at the final blood draw.  
 Compliance was quantified by how many pills were consumed. A total of eight 
pills were given to each participant. For example, a score of “7” was recorded if the 
participant took seven of the eight pills. 
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Statistical Analyses 
 All data was analyzed using IBM SPSS Statistics v.22 (Chicago, IL). Shapiro-
Wilk was used to examine normal distribution of data. Skewed data was log-transformed 
for analysis. Data was reported as mean + SE. Baseline values and changes in values 
between the control group and vitamin D group were assessed. 
 Independent t-tests were used to evaluate mean baseline BMI, serum total 25-OH, 
D, plasma Aβ1-40, METs/week, and IUs/day differences between the control group and 
vitamin D group. The Mann-Whitney test was used to assess mean age difference 
between the two groups, and to also determine whether supplement compliance differed 
between the two groups.  
 Univariate analyses of variance were used to examine mean serum total 25-OH, D 
and plasma Aβ
1-40 changes between the vitamin D group and control group. Four models 
were used to assess mean differences. The first model did not control for any variables. 
The second model controlled for the baseline measurement (i.e., either serum total 25-
OH, D or plasma Aβ
1-40
). The third model controlled for baseline measurement and 
METs/week. The fourth model controlled for baseline measurement, METs/week, and 
age. Covariates in models were determined using Pearson and Spearman correlations. A 
partial correlation was used to determine the relationship irrespective of group, using 
group as a covariate in the model.  
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CHAPTER 4 
RESULTS 
Baseline Values 
Of the 19 participants, 10 (53%) were in the vitamin D group and 9 (47%) were in 
the control group. A total of 14 females and 5 males participated. Males made up 30% of 
the vitamin D group and 22% of the control group. There was no age difference between 
the two groups (p=1.00). Although not statistically significant, BMI was higher in the 
control group (2.2 + 2.6; p=0.410), despite BMI being used to match cases during 
randomization. The reason for this is because four participants were removed from 
analysis after randomization due to missing data points. Descriptive statistics for all 23 
participants are included in Appendix K. Serum total 25-OH, D, plasma Aβ1-40, 
METs/week, and vitamin D IUs/day intake did not differ at baseline. However, plasma 
Aβ1-40 and METs/week were higher in the control group, even though differences were 
not statistically significant. The control group had a higher mean plasma Aβ1-40 by 25.0 
pg/mL (p=0.079) and higher METs/week by 553.6 (p=0.059). See Table 1. 
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Table 1 
   Mean baseline values and mean follow-up values (n=19)
a
 
 Characteristics Vitamin D group Control Group p value 
  n=10 n=9   
Baseline values   
 Male 3 2 
 Female 7 7 
 Age 62.5 + 3.4 64.3 + 4.3 1.000 
BMI 24.9 + 1.3 27.1 + 2.3 0.410 
Total 25-OH, D (ng/mL) 24.2 + 1.1 23.2 + 2.0 0.677 
Aβ1-40 (pg/mL) 106.6 + 9.1 131.6 + 9.9 0.079 
PA (METs/week)
b
 1128.9 + 219.5 575.3 + 139.8 0.059 
Vitamin D Intake (IUs/day)
b
 230.5 + 77.0 231.9 + 77.6 0.916 
Follow-up values   
 Total 25-OH, D (ng/mL) 50.7 + 1.2 22.9 + 2.1 
 Aβ1-40 (pg/mL) 121.1 + 6.0 144.4 + 8.4 
 PA (METs/week)
b
 984.0 + 253.3 555.6 + 60.0 
 Vitamin D Intake (IUs/day)
b
 323.9 + 142.7 140.4 + 38.9 
 a All values are means + SE; univariate analyses to examine group differences at baseline 
except age, which was not normally distributed and the Mann-Whitney test was used. 
b
 One missing data point in vitamin D group. 
 
Compliance 
Compliance was determined to be sufficient, as all participants but two consumed 
all eight pills. The two participants who did not consume all pills were in the vitamin D 
group, but both did consume seven pills. There was no significant compliance difference 
between the vitamin D group and control group according to the Mann-Whitney test 
(p=0.167).  
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Changes in Outcome Measurements 
 The vitamin D group mean change in serum total 25-OH, D was 538% than that 
of the control group. The mean serum total 25-OH, D increased 26.6 + 1.9 ng/mL in the 
vitamin D group, whereas its level decreased -0.3 + 1.6 ng/mL in the control group. The 
vitamin D effect size was estimated using four different models. The effect size was 
0.870 when not controlling for additional variables (p<0.001), 0.902 when controlling for 
baseline serum total 25-OH, D (p<0.001), 0.886 when controlling for baseline serum total 
25-OH, D and baseline METs/week (p<0.001), and 0.903 when controlling for baseline 
serum total 25-OH, D, baseline METs/week, and age (p<0.001). See Table 2.  
 Following the intervention, the vitamin D group had a 45% greater change in 
plasma Aβ1-40 than the control group. Mean plasma Aβ1-40 increased 14.9 + 12.0 pg/mL in 
the vitamin D group, compared to a 12.8 + 12.8 pg/mL increase in the control group. 
Four models were used to assess effect size. The effect size was 0.001 when adjusting for 
no variables (p=0.925). However, the effect size was 0.228 and statistically significant 
when controlling for baseline plasma Aβ1-40 (p=0.045). Although not significant, the 
effect size was 0.197 when controlling for baseline plasma Aβ1-40 and baseline 
METS/week (p=0.085), and 0.179 when controlling for baseline plasma Aβ1-40, baseline 
METS/week, and age (p=0.116). See Table 2. 
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Table 2 
     Mean serum vitamin D change and mean plasma Aβ1-40 change (n=19)
a 
 Characteristics Vitamin D Group Control Group %Change
c 2pη  p value 
  n=10 n=9       
Total 25-OH, D Change 
(ng/mL) 26.5 + 1.9 -0.3 + 1.6 +538% 
  Unadjusted Modelb 
   
0.870 <0.001 
Model 1 
   
0.902 <0.001 
Model 2 
   
0.886 <0.001 
Model 3 
   
0.903 <0.001 
Aβ1-40 Change (pg/mL) 14.9 + 12.0 12.8 + 12.8 +45% 
  Unadjusted Modelb 
   
0.001 0.925 
Model 1 
   
0.228 0.045 
Model 2 
   
0.197 0.085 
Model 3       0.179 0.116 
a 
All values are means + SE; univariate analysis of variance used to examine mean 
differences. 
b 
Unadjusted Model: Controlled for no additional variables. Model 1: Controlled for 
baseline value. Model 2: Controlled for baseline Aβ1-40 and METS/week. Model 3: 
Controlled for baseline Aβ1-40, METS/week, and age.  
c Vitamin D group versus control group 
 
Correlations amongst Baseline Values and Change Values 
Table 3 reports the relationship amongst baseline age, BMI, serum total 25-OH, 
D, plasma Aβ1-40, METS/week, vitamin D IUs/day, serum total 25-OH, D change, and 
plasma Aβ1-40 change. Five statistically significant relationships were observed. First, 
baseline METs/week strongly correlated with baseline plasma Aβ1-40 (Spearman R= -.83; 
p=0.002). Second, age mildly correlated with plasma Aβ1-40 change (Spearman R= -.48; 
p= 0.039). Third, baseline physical activity was mildly associated with plasma Aβ1-40 
change (Spearman R= .60; p= 0.008). Fourth, age and baseline METS/week were mildly 
  47 
related (Spearman R= -.61; p=0.008). Fifth, baseline plasma Aβ1-40 was strongly related 
to plasma Aβ1-40 change (Pearson R= -.75; p<0.001). Furthermore, the relationship 
between baseline plasma Aβ1-40 and plasma Aβ1-40 change remained significant 
independent to group difference (R= -.82; p<0.001), indicating that the reason for the 
relationship was not due to vitamin D supplementation. See Table 3. See Figure 2.   
Table 3 
        Correlation matrix for baseline values and outcome measurements (n=19) 
   1 2 3 4 5 6 7 8 
1. Ageb 
        2 BMIb -.26 
       3. Total 25-OH, Db -.19 .11 
      4. Aβ1-40b .25 -.06 .03 
     5. Physical Activityab -.61** .12 -.06 -.83** 
    6. Vitamin D Intakeac .38 .2 -.22 -.07 .11 
   7. Total 25-OH, D Changec -.19 -.09 -.08 .46 .43 -.13 
  8. Aβ1-40 Changec -.48* .07 .09 -.75** .60** -.07 -.01 
 a One missing data point in vitamin D group 
b Spearman r 
c Pearson r 
*Significance at the 0.05 level.  
**Significance at the 0.01 level.  
Mild correlation: r= .30-.49; Moderate correlation: r= .50-.69; Strong correlation: r= .70-
1.00 
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CHAPTER 5 
 
DISCUSSION 
The association between serum vitamin D and AD risk is established in the 
literature, but how vitamin D influences AD pathology has been unclear. Recent research 
suggests vitamin D up-regulates transporters that clear Aβ to the periphery, specifically 
P-gp. These studies were conducted using mouse models and human brain endothelial 
cell lines. Both experimental models showed vitamin D cleared more Aβ that was 
mediated by increased P-gp production (E. C. Chow et al., 2011; Durk et al., 2012; Durk 
et al., 2014).  
This study was an attempt to expand upon these findings using a randomized, 
double-blinded RCT design, where humans consumed one vitamin D or placebo capsule 
once a week for eight weeks. Changes in plasma Aβ1-40 and serum total 25-OH, D were 
compared between the vitamin D group and control group.  
The vitamin D supplementation protocol needed to be successful in order to 
examine plasma Aβ1-40 change differences between the groups. The vitamin D group 
almost doubled baseline serum 25-OH, D levels after finishing the eight supplements, 
whereas there was little change in serum 25-OH, D levels in the control group. 
Undeniably, the vitamin D protocol was robust.   
The vitamin D group experienced a higher plasma Aβ1-40 change than the control 
group, which was significant when controlling for baseline plasma Aβ1-40 levels. 
However, significance was lost when further controlling for age and physical activity, 
suggesting that both factors influenced overall Aβ1-40 change. This is not surprising since 
age has been previously correlated with plasma Aβ, and physical activity has been shown 
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to alter Aβ metabolism (Brown et al., 2013; Fukumoto et al., 2003). Therefore, vitamin D 
supplementation might have increased plasma Aβ1-40, but its effect was smaller and 
considered non-significant when factoring in age and physical activity.  
The observation that baseline Aβ1-40 predicts overall Aβ1-40 change is worth 
noting. The relationship was also observed independent to group difference, meaning that 
an increase in plasma Aβ1-40 was greater in those started with lower levels regardless of 
vitamin D supplementation.  
Peripheral Sink Hypothesis 
The literature suggests that brain Aβ and peripheral free Aβ have homeostatic 
tendencies, essentially operating as a concentration gradient. It has been suggested that 
brain Aβ will only be cleared if the periphery Aβ concentration is lowered. Indeed, 
several experimental models have shown peripheral Aβ degradation reduces cerebral Aβ 
burden (Marques et al., 2009; Vasilevko, Xu, Previti, Van Nostrand, & Cribbs, 2007). On 
the contrary, recent evidence points against the periphery sink hypothesis. For example, 
selective peripheral BACE1 inhibition decreased peripheral Aβ, but did not alter cerebral 
Aβ in mice (Georgievska et al., 2015). Likewise, cerebral Aβ levels did not decrease 
following neprilysin-induced peripheral Aβ degradation in non-human primates 
(Henderson et al., 2014). However, BBB function was not evaluated in such studies. For 
Aβ to be cleared, a functional BBB with a sufficient amount of active transporters would 
theoretically have to be available (Wildsmith et al., 2013) 
The fact that these study participants with low baseline Aβ1-40 levels experienced 
a greater Aβ1-40 change after vitamin D supplementation might be explained by a 
peripheral sink mechanism. Low baseline Aβ1-40 levels in the periphery could suggest that 
  51 
there are not enough P-gp transporters to transport Aβ, leading to an inability to achieve 
Aβ homeostasis. In theory, vitamin D would allow for Aβ homeostasis by producing 
more P-gp. The intent of this study was to increase Aβ1-40 by increasing the amount of P-
gp. Nevertheless, controls also experienced a greater Aβ1-40 change when baseline Aβ1-40 
levels were low. Additionally, low plasma Aβ1-40 might also indicate low brain Aβ1-40 
production. Therefore, it cannot be certain that a peripheral sink mechanism was 
observed.  
Physical Activity Mechanisms 
 Epidemiological data suggest physical activity decreases AD risk (Scarmeas et al., 
2009). The pathways for which physical activity decreases AD risk are related to the 
cardiovascular system, but recent evidence suggests it also modulates Aβ metabolism. 
Brown et al. (2013) examined the effect of physical activity on plasma Aβ1-40 and plasma 
Aβ1-42. Lower levels of physical activity were associated with a higher Aβ42:40 ratio, 
suggesting that physical activity modulates Aβ metabolism. No association between 
plasma Aβ1-40 and physical activity was found by Brown et al. (2013), whereas these 
findings did suggest an association. Nonetheless, this study is in agreement that Aβ 
metabolism might be influenced by physical activity levels. Being that the mean plasma 
Aβ1-40 change between the vitamin D group and control group was not significant after 
controlling for physical activity, more research regarding the effect of physical activity 
on AD pathology is warranted.   
Immunological Mechanisms 
 Macrophage activity has been found to be lower in AD brains, leading to an 
inability to degrade brain Aβ, but vitamin D has been shown to restore innate immunity 
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function in the brain. Experimental models have shown vitamin D to activate type II 
macrophages (Mizwickia et al., 2012). Hence, increasing circulating vitamin D has the 
potential to increase brain Aβ degradation via the restoration of innate immunity. 
Immune mechanisms were not evaluated in this study. Although evidence points towards 
vitamin D increasing Aβ transport out of the brain, future attempts to assess clearance 
must also consider its potential immunological effects.  
Peripheral Etiology  
 The etiology of AD has been theorized to start in the periphery and manifest in 
the brain. Brain Aβ has been associated with AD, but the brain is not the lone source of 
Aβ production. For example, platelets are a major source of Aβ. Platelet-secreted can 
enter the brain from the periphery. Many prior attempts to alter Aβ pathology have 
focused specifically on disrupting brain Aβ metabolism, despite the fact that platelets 
produce nearly 90% of Aβ in the blood (Chen, Inestrosa, Ross, & Fernandez, 1995). New 
perspectives in AD treatment even involve targeting peripheral Aβ (Decourt et al., 2013).  
 The intent of this study was to measure brain Aβ clearance indirectly by assessing 
plasma Aβ1-40 change. Being that platelets produce the majority of blood Aβ, the effects 
of vitamin D on peripheral Aβ metabolism need to be considered. Evidence suggests that 
vitamin D up-regulates neprilysin production, one of the enzymes that can degrade Aβ1-40 
even in the periphery (Grimm et al., 2014; Henderson et al., 2014). Therefore, perhaps 
vitamin D also influences peripheral-based Aβ degradation.  
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Validity and Reliability 
Blood-based 
 For plasma Aβ1-40, ELISA tests were run in duplicates and the mean intrassay 
coefficient of variation was 6.5%. Mean plasma Aβ1-40 measurements were consistent 
with previously reported data that measured Aβ1-40 using an ELISA technique (Brown et 
al., 2013). The amount of Aβ1-40 change was also within the range of previously reported 
changes in intervention-based studies (DiSilvestro et al., 2012; Flicker et al., 2008). For 
serum total 25-OH, D, all participants in this study had levels less than 30 ng/mL. This 
cutoff was determined by examining when PTH levels plateaued with serum total 25-OH, 
D levels (Chapuy et al., 1997).  
Questionnaire 
 The vitamin D IUs/d mean of this study population was similar to the range 
reported in the BVDQ validation study (Hacker-Thompson et al., 2012). The METs/week 
mean of this study population was within the ACSM recommendation of 500-1000 
METs/week (Garber et al., 2011). Hence, both surveys did not produce abnormal 
measurements.  
Strengths 
 This study has many strengths. This was the first study to examine the effect of 
vitamin D supplementation on AD pathology in humans using non-psychological 
measurements. The only way to detect AD pathological modulations in younger people is 
with outcome measurements that are not cognitively based. Furthermore, only people 
with insufficient serum vitamin D, according to LC-MS/MS technology, were included. 
The LC-MS/MS measurement technology is considered to be the most accurate of all 
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vitamin D assays (Roth, Schmidt-Gayk, Weber, & Niederau, 2008). This ensured that the 
effect of vitamin D supplementation on vitamin D status could accurately be quantified. 
Overall, this study was a novel concept that expanded upon recent in vitro and in vivo 
studies quickly.  
Limitations 
There are several limitations to this study. First, although the vitamin D group 
experienced an increased plasma Aβ1-40, so did the control group. Baseline plasma Aβ1-40 
also correlated with plasma Aβ1-40 change independent to group difference. There are 
several possible reasons for this. One reason is that only free plasma Aβ1-40 was 
measured. Another reason is that Aβ1-40 is produced by peripheral organs, including the 
pancreas, liver, and platelets, and can also bind to plasma proteins (Kuo et al., 2000; 
Roher et al., 2009). Even the participant’s state during the blood draw also might impact 
plasma Aβ measurements, (e.g., hydration status). Second, physical activity and vitamin 
D intake data were self-reported and ought to be interpreted with caution due to the 
possibility of measurement error. Third, additional dietary data was not collected, such as 
caffeine intake and overall macronutrient and micronutrient composition. Fourth, the 
ApoE4 allele was not controlled for, which is strongly associated with AD pathology. As 
a substitute, all participants on statins were excluded because ApoE4 is associated with 
high serum cholesterol (Bennet et al., 2007). Fifth, generalizability is limited because of a 
small sample size. Finally, participants were Arizona residents, non-diabetic, without 
dementia, not taking statins, without kidney disease, and without blood disorders. As 
such, results cannot be generalizable to individuals who do not have these characteristics.   
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CHAPTER 6 
CONCLUSION 
Findings from this research suggest that vitamin D supplementation might 
enhance brain Aβ transportation to the periphery. In this study, those receiving the 
vitamin D supplement experienced a greater plasma Aβ1-40 change than those receiving a 
placebo. The effect was considered significant when controlling for baseline Aβ1-40, but 
was considered to be non-significant when controlling for physical activity and age.  
This study is considered a pilot study because it was the first of its kind, the 
sample size was small, there are additional plasma Aβ measurement tools, and 
supplementary measurements could be included to improve validity. This study sample 
size was 19, although a sample size of roughly 600 was calculated using previous studies 
that used plasma Aβ1-40 as an outcome measurement. Additionally, the INNO-BIA 
plasma Aβ assay, which uses xMAP technology, has become increasingly popular in the 
literature because it measures Aβ1-40, Aβ1-42, and its truncated forms simultaneously with 
high precision (Lachnoa et al., 2012). To ensure homogeneity and reproducibility, future 
studies should consider measuring plasma Aβ with this technology. Validity can also be 
improved by including supplementary outcome measurements to plasma Aβ. For 
example, including TNF-α, IL-6, neprilysin, and BACE1 blood measurements might 
provide further insight to how vitamin D modulates AD pathology. Evaluating TNF-α, 
IL-6, and neprilysin would offer more insight into possible immunological mechanisms, 
and BACE1 measurements would provide information about peripheral Aβ metabolism. 
Using vitamin D as a mode to identify AD pharmaceutical targets is a justifiable 
strategy to develop successful treatments. Vitamin D can be used to monitor cellular 
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changes in order to help understand AD pathology. The ultimate conclusion as a result 
from more vitamin D research might not exclusively be a vitamin D supplementation 
recommendation, but also the identification of additional powerful agents that can 
modulate AD pathology.  
  57 
REFERENCES 
Alexopoulos, G., Jeste, D., Chung, H., Carpenter, D., Ross, R., & Docherty, J. (2007). 
The expert consensus guideline series. Treatment of dementia and its behavioral 
disturbances. Introduction: methods, commentary, and summary. J Psychiatr 
Pract, 13(3), 207-216.  
Allen, S. J., Watson, J. J., & Dawbarn, D. (2011). The neurotrophins and their role in 
Alzheimer's disease. Current neuropharmacology, 9(4), 559-573. doi: 
10.2174/157015911798376190 [doi] 
Alley, G. M., Bailey, J. A., Chen, D., Ray, B., Puli, L. K., Tanila, H., . . . Lahiri, D. K. 
(2010). Memantine lowers amyloid‐β peptide levels in neuronal cultures and in 
APP/PS1 transgenic mice. Journal of neuroscience research, 88(1), 143-154.  
Alzheimer’s, A. (2015). 2015 Alzheimer's disease facts and figures. Alzheimer's & 
dementia: the journal of the Alzheimer's Association, 11(3), 332.  
American Psychiatric, A., & Task Force on, D.-I. (2000). Diagnostic and statistical 
manual of mental disorders: DSM-IV-TR. Washington, DC: American Psychiatric 
Association. 
Annweiler, C., Fantino, B., Gautier, J., Beaudenon, M., Thiery, S., & Beauchet, O. 
(2012). Cognitive Effects of Vitamin D Supplementation in Older Outpatients 
Visiting a Memory Clinic: A Pre–Post Study. Journal of the American Geriatrics 
Society, 60(4), 793-795.  
Annweiler, C., Fantino, B., Schott, A., Krolak‐Salmon, P., Allali, G., & Beauchet, O. 
(2012). Vitamin D insufficiency and mild cognitive impairment: cross‐sectional 
association. European Journal of Neurology, 19(7), 1023-1029.  
Annweiler, C., Rolland, Y., Schott, A. M., Blain, H., Vellas, B., Herrmann, F. R., & 
Beauchet, O. (2012). Higher vitamin D dietary intake is associated with lower risk 
of Alzheimer’s disease: a 7-year follow-up. The Journals of Gerontology Series 
A: Biological Sciences and Medical Sciences, 67(11), 1205-1211.  
Arevalo, M. A., Roldan, P. M., Chacon, P. J., & Rodriguez-Tebar, A. (2009). Amyloid 
beta serves as an NGF-like neurotrophic factor or acts as a NGF antagonist 
depending on its concentration. Journal of neurochemistry, 111(6), 1425-1433.  
  58 
Arispe, N., Rojas, E., & Pollard, H. B. (1993). Alzheimer disease amyloid beta protein 
forms calcium channels in bilayer membranes: blockade by tromethamine and 
aluminum. Proceedings of the National Academy of Sciences, 90(2), 567-571.  
Balion, C., Griffith, L. E., Strifler, L., Henderson, M., Patterson, C., Heckman, G., . . . 
Raina, P. (2012). Vitamin D, cognition, and dementia A systematic review and 
meta-analysis. Neurology, 79(13), 1397-1405.  
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., . . . Burns, A. 
(2011). Sertraline or mirtazapine for depression in dementia (HTA-SADD): a 
randomised, multicentre, double-blind, placebo-controlled trial. Lancet, 
378(9789), 403-411. doi: 10.1016/S0140-6736(11)60830-1 [doi] 
Barnard, K., & Colón-Emeric, C. (2010). Extraskeletal effects of vitamin D in older 
adults: cardiovascular disease, mortality, mood, and cognition. The American 
journal of geriatric pharmacotherapy, 8(1), 4-33.  
Barnes, D. E., & Yaffe, K. (2011). The projected effect of risk factor reduction on 
Alzheimer's disease prevalence. The Lancet Neurology, 10(9), 819-828.  
Bayer-Carter, J. L., Green, P. S., Montine, T. J., VanFossen, B., Baker, L. D., Watson, G. 
S., . . . Walter, B. K. (2011). Diet intervention and cerebrospinal fluid biomarkers 
in amnestic mild cognitive impairment. Archives of Neurology, 68(6), 743-752.  
Bear, M. F., Connors, B. W., & Paradiso, M. A. (2007). Neuroscience (Vol. 2): 
Lippincott Williams & Wilkins. 
Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., . . . 
Danesh, J. (2007). Association of apolipoprotein E genotypes with lipid levels and 
coronary risk. Jama, 298(11), 1300-1311. doi: 298/11/1300 [pii] 
Berti, V., Murray, J., Davies, M., Spector, N., Tsui, W., LI, Y., . . . McHugh, P. (2014). 
Nutrient patterns and brain biomarkers of Alzheimer’s disease in cognitively 
normal individuals. The journal of nutrition, health & aging, 1-11.  
Bharate, J. B., Batarseh, Y. S., Wani, A., Sharma, S., Vishwakarma, R. A., Kaddoumi, 
A., . . . Bharate, S. B. (2015). Synthesis and P-glycoprotein induction activity of 
colupulone analogs. Organic & biomolecular chemistry, 13(19), 5488-5496.  
  59 
Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A., . . . Hyde, C. 
(2012). The effectiveness and cost-effectiveness of donepezil, galantamine, 
rivastigmine and memantine for the treatment of Alzheimer's disease (review of 
Technology Appraisal No. 111): a systematic review and economic model. Health 
technology assessment (Winchester, England), 16(21), 1-470. doi: 
10.3310/hta16210 [doi] 
Brenn, A., Grube, M., Jedlitschky, G., Fischer, A., Strohmeier, B., Eiden, M., . . . 
Vogelgesang, S. (2014). St. John's Wort reduces beta-amyloid accumulation in a 
double transgenic Alzheimer's disease mouse model-role of P-glycoprotein. Brain 
pathology (Zurich, Switzerland), 24(1), 18-24. doi: 10.1111/bpa.12069 [doi] 
Brookmeyer, R., Johnson, E., Ziegler-Graham, K., & Arrighi, H. M. (2007). Forecasting 
the global burden of Alzheimer's disease. Alzheimer's & dementia : the journal of 
the Alzheimer's Association, 3(3), 186-191. doi: 10.1016/j.jalz.2007.04.381 [doi] 
Brown, B. M., Peiffer, J. J., Taddei, K., Lui, J. K., Laws, S. M., Gupta, V. B., . . . 
Martins, R. N. (2013). Physical activity and amyloid-beta plasma and brain levels: 
results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. 
Molecular psychiatry, 18(8), 875-881. doi: 10.1038/mp.2012.107 [doi] 
Buell, J. S., Scott, T. M., Dawson-Hughes, B., Dallal, G. E., Rosenberg, I. H., Folstein, 
M. F., & Tucker, K. L. (2009). Vitamin D is associated with cognitive function in 
elders receiving home health services. The Journals of Gerontology Series A: 
Biological Sciences and Medical Sciences, 64(8), 888-895.  
Chapuy, M.-C., Preziosi, P., Maamer, M., Arnaud, S., Galan, P., Hercberg, S., & 
Meunier, P. (1997). Prevalence of vitamin D insufficiency in an adult normal 
population. Osteoporosis International, 7(5), 439-443.  
Chen, M., Inestrosa, N. C., Ross, G. S., & Fernandez, H. L. (1995). Platelets are the 
primary source of amyloid β-peptide in human blood. Biochemical and 
biophysical research communications, 213(1), 96-103.  
Cheng, G., Huang, C., Deng, H., & Wang, H. (2012). Diabetes as a risk factor for 
dementia and mild cognitive impairment: a meta‐analysis of longitudinal 
studies. Internal medicine journal, 42(5), 484-491.  
  60 
Chouraki, V., Beiser, A., Younkin, L., Preis, S. R., Weinstein, G., Hansson, O., . . . 
Launer, L. (2014). Plasma amyloid-β and risk of Alzheimer's disease in the 
Framingham Heart Study. Alzheimer's & Dementia.  
Chow, E. C., Durk, M. R., Cummins, C. L., & Pang, K. S. (2011). 1Alpha,25-
dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and 
not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and 
brain efflux of digoxin in mice in vivo. J Pharmacol Exp Ther, 337(3), 846-859. 
doi: 10.1124/jpet.111.179101 
Chow, E. C., Sun, H., Khan, A. A., Groothuis, G. M., & Pang, K. S. (2010). Effects of 1
α, 25‐dihydroxyvitamin D3 on transporters and enzymes of the rat intestine and 
kidney in vivo. Biopharmaceutics & drug disposition, 31(1), 91-108.  
Chow, V. W., Mattson, M. P., Wong, P. C., & Gleichmann, M. (2010). An overview of 
APP processing enzymes and products. Neuromolecular medicine, 12(1), 1-12. 
doi: 10.1007/s12017-009-8104-z [doi] 
Cirrito, J. R., Deane, R., Fagan, A. M., Spinner, M. L., Parsadanian, M., Finn, M. B., . . . 
Holtzman, D. M. (2005). P-glycoprotein deficiency at the blood-brain barrier 
increases amyloid-beta deposition in an Alzheimer disease mouse model. The 
Journal of clinical investigation, 115(11), 3285-3290. doi: 10.1172/JCI25247 
[doi] 
Corless, D., Ellis, M., Dawson, E., Fraser, F., Evans, S., Perry, J., . . . Boucher, B. (1987). 
Using activities of daily living assessments to measure the effectiveness of 
vitamin D supplements in elderly long-stay patients. The British Journal of 
Occupational Therapy, 50(2), 60-62.  
Costa, M., Ortiz, A. M., & Jorquera, J. I. (2012). Therapeutic Albumin Binding to 
Remove Amyloid-β. Journal of Alzheimer's Disease, 29(1), 159-170.  
Decourt, B., Walker, A., Gonzales, A., Malek-Ahmadi, M., Liesback, C., Davis, K. J., . . . 
Sabbagh, M. N. (2013). Can platelet BACE1 levels be used as a biomarker for 
Alzheimer's disease? Proof-of-concept study. Platelets, 24(3), 235-238. doi: 
10.3109/09537104.2012.688899 [doi] 
  61 
DeKosky, S. T., & Scheff, S. W. (1990). Synapse loss in frontal cortex biopsies in 
Alzheimer's disease: correlation with cognitive severity. Annals of Neurology, 
27(5), 457-464. doi: 10.1002/ana.410270502 [doi] 
Del Valle, H. B., Yaktine, A. L., Taylor, C. L., & Ross, A. C. (2011). Dietary reference 
intakes for calcium and vitamin D: National Academies Press. 
Di Santo, S. G., Prinelli, F., Adorni, F., Caltagirone, C., & Musicco, M. (2013). A meta-
analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine 
in relation to severity of Alzheimer's disease. Journal of Alzheimer's Disease, 
35(2), 349-361.  
DiSilvestro, R. A., Joseph, E., Zhao, S., & Bomser, J. (2012). Diverse effects of a low 
dose supplement of lipidated curcumin in healthy middle aged people. Nutrition 
journal, 11, 79-2891-2811-2879. doi: 10.1186/1475-2891-11-79 [doi] 
Dong, J., Wong, S. L., Lau, C. W., Lee, H. K., Ng, C. F., Zhang, L., . . . Huang, Y. 
(2012). Calcitriol protects renovascular function in hypertension by down-
regulating angiotensin II type 1 receptors and reducing oxidative stress. European 
heart journal, 33(23), 2980-2990.  
Doody, R., Stevens, J., Beck, C., Dubinsky, R., Kaye, J., Gwyther, L., . . . DeKosky, S. 
(2001). Practice parameter: management of dementia (an evidence-based review) 
report of the quality standards subcommittee of the American Academy of 
Neurology. Neurology, 56(9), 1154-1166.  
Durk, M. R., Chan, G. N., Campos, C. R., Peart, J. C., Chow, E. C., Lee, E., . . . Pang, K. 
S. (2012). 1alpha,25-Dihydroxyvitamin D3-liganded vitamin D receptor increases 
expression and transport activity of P-glycoprotein in isolated rat brain capillaries 
and human and rat brain microvessel endothelial cells. Journal of neurochemistry, 
123(6), 944-953. doi: 10.1111/jnc.12041 [doi] 
Durk, M. R., Han, K., Chow, E. C., Ahrens, R., Henderson, J. T., Fraser, P. E., & Pang, 
K. S. (2014). 1alpha,25-Dihydroxyvitamin D3 reduces cerebral amyloid-beta 
accumulation and improves cognition in mouse models of Alzheimer's disease. 
The Journal of neuroscience : the official journal of the Society for Neuroscience, 
34(21), 7091-7101. doi: 10.1523/JNEUROSCI.2711-13.2014 [doi] 
  62 
Eyles, D. W., Smith, S., Kinobe, R., Hewison, M., & McGrath, J. J. (2005). Distribution 
of the vitamin D receptor and 1α-hydroxylase in human brain. Journal of 
chemical neuroanatomy, 29(1), 21-30.  
F Holick, M. (2011). Vitamin D: evolutionary, physiological and health perspectives. 
Current Drug Targets, 12(1), 4-18.  
Ferrer, I., Marín, C., Rey, M. J., Ribalta, T., Goutan, E., Blanco, R., . . . Martí, E. (1999). 
BDNF and full-length and truncated TrkB expression in Alzheimer disease. 
Implications in therapeutic strategies. Journal of Neuropathology & Experimental 
Neurology, 58(7), 729-739.  
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., . . . 
Alzheimer's Disease, I. (2005). Global prevalence of dementia: a Delphi 
consensus study. Lancet, 366(9503), 2112-2117. doi: S0140-6736(05)67889-0 
[pii] 
Fishel, M. A., Watson, G. S., Montine, T. J., Wang, Q., Green, P. S., Kulstad, J. J., . . . 
Craft, S. (2005). Hyperinsulinemia provokes synchronous increases in central 
inflammation and beta-amyloid in normal adults. Archives of Neurology, 62(10), 
1539-1544. doi: 62/10/1539 [pii] 
Flicker, L., Martins, R. N., Thomas, J., Acres, J., Taddei, K., Vasikaran, S. D., . . . 
Almeida, O. P. (2008). B-vitamins reduce plasma levels of beta amyloid. 
Neurobiology of aging, 29(2), 303-305. doi: S0197-4580(06)00383-6 [pii] 
Fortmann, S. P., Burda, B. U., Senger, C. A., Lin, J. S., Beil, T. L., O'Connor, E., & 
Whitlock, E. P. (2013). Vitamin, Mineral, and Multivitamin Supplements for the 
Primary Prevention of Cardiovascular Disease and Cancer.  
Fukumoto, H., Tennis, M., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. 
C. (2003). Age but not diagnosis is the main predictor of plasma amyloid β-
protein levels. Archives of Neurology, 60(7), 958-964.  
Gao, Y., Huang, C., Zhao, K., Ma, L., Qiu, X., Zhang, L., . . . Huang, C. (2013). 
Depression as a risk factor for dementia and mild cognitive impairment: a meta‐
analysis of longitudinal studies. International journal of geriatric psychiatry, 
28(5), 441-449.  
  63 
Garber, C. E., Blissmer, B., Deschenes, M. R., Franklin, B. A., Lamonte, M. J., Lee, I.-
M., . . . Swain, D. P. (2011). American College of Sports Medicine position stand. 
Quantity and quality of exercise for developing and maintaining cardiorespiratory, 
musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance 
for prescribing exercise. Medicine and science in sports and exercise, 43(7), 
1334-1359.  
Gareri, P., Putignano, D., Castagna, A., Cotroneo, A. M., De Palo, G., Fabbo, A., . . . 
Marino, S. (2014). Retrospective study on the benefits of combined Memantine 
and cholinEsterase inhibitor treatMent in AGEd patients affected with 
Alzheimer's disease: the MEMAGE Study. Journal of Alzheimer's Disease, 41(2), 
633-640.  
Garzon, D. J., & Fahnestock, M. (2007). Oligomeric amyloid decreases basal levels of 
brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of 
BDNF transcripts IV and V in differentiated human neuroblastoma cells. The 
Journal of neuroscience, 27(10), 2628-2635.  
Georgievska, B., Gustavsson, S., Lundkvist, J., Neelissen, J., Eketjäll, S., Ramberg, V., . . 
. Svensson, S. (2015). Revisiting the peripheral sink hypothesis: inhibiting 
BACE1 activity in the periphery does not alter β‐amyloid levels in the CNS. 
Journal of neurochemistry, 132(4), 477-486.  
Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., . . . Frangione, B. 
(2004). Systemic catabolism of Alzheimer's Abeta40 and Abeta42. The Journal of 
biological chemistry, 279(44), 45897-45908. doi: 10.1074/jbc.M407668200 [doi] 
Giacomello, M., Drago, I., Pizzo, P., & Pozzan, T. (2007). Mitochondrial Ca2&plus; as a 
key regulator of cell life and death. Cell Death & Differentiation, 14(7), 1267-
1274.  
Good, T. A., Smith, D. O., & Murphy, R. M. (1996). Beta-amyloid peptide blocks the 
fast-inactivating K+ current in rat hippocampal neurons. Biophysical journal, 
70(1), 296-304. doi: S0006-3495(96)79570-X [pii] 
Grimm, M. O., Lehmann, J., Mett, J., Zimmer, V. C., Grösgen, S., Stahlmann, C. P., . . . 
Herr, C. (2014). Impact of Vitamin D on Amyloid Precursor Protein Processing 
and Amyloid-β Peptide Degradation in Alzheimer's Disease. Neurodegenerative 
Diseases, 13(2-3), 75-81.  
  64 
Gropper, S., & Smith, J. (2008). Advanced Nutrition and Human Metabolism: Cengage 
Learning. 
Hacker-Thompson, A., Schloetter, M., & Sellmeyer, D. E. (2012). Validation of a dietary 
vitamin D questionnaire using multiple diet records and the block 98 health habits 
and history questionnaire in healthy postmenopausal women in northern 
California. Journal of the Academy of Nutrition and Dietetics, 112(3), 419-423.  
Hamer, M., & Chida, Y. (2009). Physical activity and risk of neurodegenerative disease: 
a systematic review of prospective evidence. Psychological medicine, 39(01), 3-
11.  
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., . . . Hoessler, Y. 
C. (2010). Biomarkers for Alzheimer's disease: academic, industry and regulatory 
perspectives. Nature Reviews Drug Discovery, 9(7), 560-574.  
Hartz, A. M., Miller, D. S., & Bauer, B. (2010). Restoring blood-brain barrier P-
glycoprotein reduces brain amyloid-β in a mouse model of Alzheimer's disease. 
Molecular pharmacology, 77(5), 715-723.  
Haussler, M. R., Haussler, C. A., Bartik, L., Whitfield, G. K., Hsieh, J.-C., Slater, S., & 
Jurutka, P. W. (2008). Vitamin D receptor: molecular signaling and actions of 
nutritional ligands in disease prevention. Nutrition reviews, 66(suppl 2), S98-
S112.  
Henderson, S. J., Andersson, C., Narwal, R., Janson, J., Goldschmidt, T. J., Appelkvist, 
P., . . . Tebbe, J. (2014). Sustained peripheral depletion of amyloid-β with a 
novel form of neprilysin does not affect central levels of amyloid-β. Brain, 
137(2), 553-564.  
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., . . . Smith, 
M. A. (2001). Mitochondrial abnormalities in Alzheimer's disease. The Journal of 
neuroscience : the official journal of the Society for Neuroscience, 21(9), 3017-
3023. doi: 21/9/3017 [pii] 
Hobart, J., Cano, S., Posner, H., Selnes, O., Stern, Y., Thomas, R., . . . Initiative, A. s. D. 
N. (2013). Putting the Alzheimer’s cognitive test to the test I: Traditional 
psychometric methods. Alzheimer's & Dementia, 9(1), S4-S9.  
  65 
Hock, C., Heese, K., Hulette, C., Rosenberg, C., & Otten, U. (2000). Region-specific 
neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived 
neurotrophic factor and increased levels of nerve growth factor in hippocampus 
and cortical areas. Archives of Neurology, 57(6), 846-851.  
Holick, M., Matsuoka, L., & Wortsman, J. (1989). Age, vitamin D, and solar ultraviolet. 
The Lancet, 334(8671), 1104-1105.  
Hsieh, S., Schubert, S., Hoon, C., Mioshi, E., & Hodges, J. R. (2013). Validation of the 
Addenbrooke's Cognitive Examination III in Frontotemporal Dementia and 
Alzheimer's Disease. Dementia and geriatric cognitive disorders(36), 242-250.  
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013). 
Monetary costs of dementia in the United States. New England Journal of 
Medicine, 368(14), 1326-1334.  
Hynd, M. R., Scott, H. L., & Dodd, P. R. (2004). Differential expression of N‐methyl‐
d‐aspartate receptor NR2 isoforms in Alzheimer's disease. Journal of 
neurochemistry, 90(4), 913-919.  
Jacobsen, J. S., Wu, C.-C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., . . . 
Reinhart, P. H. (2006). Early-onset behavioral and synaptic deficits in a mouse 
model of Alzheimer's disease. Proceedings of the National Academy of Sciences 
of the United States of America, 103(13), 5161-5166.  
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H. P., & van den Bussche, H. 
(2005). Cholinesterase inhibitors for patients with Alzheimer's disease: systematic 
review of randomised clinical trials. BMJ (Clinical research ed.), 331(7512), 321-
327. doi: 331/7512/321 [pii] 
Karakaya, T., Fußer, F., Schröder, J., & Pantel, J. (2013). Pharmacological Treatment of 
Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer´ s Disease. 
Current neuropharmacology, 11(1), 102.  
Karantzoulis, S., & Galvin, J. E. (2011). Distinguishing Alzheimer's disease from other 
major forms of dementia. Expert review of neurotherapeutics, 11(11), 1579-1591. 
doi: 10.1586/ern.11.155 [doi] 
  66 
Kennel, K. A., Drake, M. T., & Hurley, D. L. (2010). Vitamin D deficiency in adults: 
when to test and how to treat. Paper presented at the Mayo Clinic Proceedings. 
Khatri, N., & Man, H. Y. (2013). Synaptic activity and bioenergy homeostasis: 
implications in brain trauma and neurodegenerative diseases. Frontiers in 
neurology, 4, 199. doi: 10.3389/fneur.2013.00199 [doi] 
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., . . . 
Estrada, S. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh 
Compound‐B. Annals of Neurology, 55(3), 306-319.  
Koyama, A., Okereke, O. I., Yang, T., Blacker, D., Selkoe, D. J., & Grodstein, F. (2012). 
Plasma amyloid-beta as a predictor of dementia and cognitive decline: a 
systematic review and meta-analysis. Archives of Neurology, 69(7), 824-831. doi: 
archneurol.2011.1841 [pii] 
Kroker, K. S., Moreth, J., Kussmaul, L., Rast, G., & Rosenbrock, H. (2013). Restoring 
long-term potentiation impaired by amyloid-beta oligomers: comparison of an 
acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists. 
Brain research bulletin, 96, 28-38.  
Kuhnke, D., Jedlitschky, G., Grube, M., Krohn, M., Jucker, M., Mosyagin, I., . . . 
Vogelgesang, S. (2007). MDR1-P-Glycoprotein (ABCB1) Mediates Transport of 
Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta 
clearance at the blood-brain barrier. Brain pathology (Zurich, Switzerland), 17(4), 
347-353. doi: BPA075 [pii] 
Kuo, Y.-M., Kokjohn, T. A., Kalback, W., Luehrs, D., Galasko, D. R., Chevallier, N., . . . 
Roher, A. E. (2000). Amyloid-β peptides interact with plasma proteins and 
erythrocytes: implications for their quantitation in plasma. Biochemical and 
biophysical research communications, 268(3), 750-756.  
Lachnoa, D. R., Emersonb, J. K., Vanderstichelec, H., Gonzalesd, C., Martényid, F., 
Konradd, R. J., . . . Deand, R. A. (2012). Validation of a Multiplex Assay for 
Simultaneous Quantification of Amyloid-ß Peptide Species in Human Plasma 
with Utility for Measurements in Studies of Alzheimer’s Disease Therapeutics. 
Journal of Alzheimer’s Disease, 32, 1-4.  
  67 
Lacor, P. N., Buniel, M. C., Furlow, P. W., Clemente, A. S., Velasco, P. T., Wood, M., . . 
. Klein, W. L. (2007). Aβ oligomer-induced aberrations in synapse composition, 
shape, and density provide a molecular basis for loss of connectivity in 
Alzheimer's disease. The Journal of neuroscience, 27(4), 796-807.  
Lam, F. C., Liu, R., Lu, P., Shapiro, A. B., Renoir, J. M., Sharom, F. J., & Reiner, P. B. 
(2001). beta-Amyloid efflux mediated by p-glycoprotein. Journal of 
neurochemistry, 76(4), 1121-1128.  
Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in 
neurodegenerative diseases. Nature, 443(7113), 787-795.  
Lipton, S. A. (2005). The molecular basis of memantine action in Alzheimer's disease 
and other neurologic disorders: low-affinity, uncompetitive antagonism. Current 
Alzheimer research, 2(2), 155-165.  
Littlejohns, T. J., Henley, W. E., Lang, I. A., Annweiler, C., Beauchet, O., Chaves, P. H., 
. . . Langa, K. M. (2014). Vitamin D and the risk of dementia and Alzheimer 
disease. Neurology, 83(10), 920-928.  
Llewellyn, D. J., Lang, I. A., Langa, K. M., & Melzer, D. (2010). Vitamin D and 
cognitive impairment in the elderly US population. The Journals of Gerontology 
Series A: Biological Sciences and Medical Sciences, glq185.  
Llewellyn, D. J., Langa, K. M., & Lang, I. A. (2009). Serum 25-hydroxyvitamin D 
concentration and cognitive impairment. Journal of geriatric psychiatry and 
neurology, 22(3), 188-195.  
Loeb, M. B., Molloy, D. W., Smieja, M., Standish, T., Goldsmith, C. H., Mahony, J., . . . 
Davidson, W. (2004). A randomized, controlled trial of doxycycline and rifampin 
for patients with Alzheimer's disease. Journal of the American Geriatrics Society, 
52(3), 381-387.  
MacDonald, P. N., Baudino, T. A., Tokumaru, H., Dowd, D. R., & Zhang, C. (2001). 
Vitamin D receptor and nuclear receptor coactivators: crucial interactions in 
vitamin D-mediated transcription. Steroids, 66(3), 171-176.  
Manczak, M., Mao, P., Calkins, M. J., Cornea, A., Reddy, A. P., Murphy, M. P., . . . 
Reddy, P. H. (2010). Mitochondria-targeted antioxidants protect against amyloid-
  68 
β toxicity in Alzheimer's disease neurons. Journal of Alzheimer's Disease, 20, 
609-631.  
Marques, M. A., Kulstad, J. J., Savard, C. E., Green, P. S., Lee, S. P., Craft, S., . . . Cook, 
D. G. (2009). Peripheral amyloid-β levels regulate amyloid-β clearance from 
the central nervous system. Journal of Alzheimer's disease: JAD, 16(2), 325.  
Mattsson, N., Insel, P. S., Aisen, P. S., Jagust, W., Mackin, S., Weiner, M., . . . 
Trojanowki, J. Q. (2015). Brain structure and function as mediators of the effects 
of amyloid on memory. Neurology, 84(11), 1136-1144.  
Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., . . . 
Ewers, M. (2009). CSF biomarkers and incipient Alzheimer disease in patients 
with mild cognitive impairment. Jama, 302(4), 385-393.  
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., . . . 
Bateman, R. J. (2010). Decreased clearance of CNS β-amyloid in Alzheimer’s 
disease. Science, 330(6012), 1774-1774.  
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. 
H., . . . Mayeux, R. (2011). The diagnosis of dementia due to Alzheimer’s 
disease: Recommendations from the National Institute on Aging-Alzheimer’s 
Association workgroups on diagnostic guidelines for Alzheimer's disease. 
Alzheimer's & Dementia, 7(3), 263-269.  
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006). Memantine for dementia. The 
Cochrane database of systematic reviews, (2)(2), CD003154. doi: 
10.1002/14651858.CD003154.pub5 [doi] 
Mesulam, M. (2004). The cholinergic lesion of Alzheimer's disease: pivotal factor or side 
show? Learning & Memory, 11(1), 43-49.  
Meunier, C., Montérémal, J., Faure, P., & Ducros, V. (2015). Four years of LC–MS/MS 
method for quantification of 25-hydroxyvitamin D (D2+ D3) for clinical practice. 
Journal of Chromatography B, 989, 54-61.  
  69 
Miller, D. S., Nobmann, S. N., Gutmann, H., Toeroek, M., Drewe, J., & Fricker, G. 
(2000). Xenobiotic transport across isolated brain microvessels studied by 
confocal microscopy. Molecular pharmacology, 58(6), 1357-1367.  
Mizwickia, M. T., Menegaza, D., Zhangb, J., Barrientos-Durána, A., Tsec, S., Cashmand, 
J. R., . . . Fialac, M. (2012). Genomic and nongenomic signaling induced by 1α, 
25 (OH) 2-vitamin D3 promotes the recovery of amyloid-ß phagocytosis by 
Alzheimer’s disease macrophages. Journal of Alzheimer’s Disease, 29, 1-4.  
Morris, J. C. (2005). Early-stage and preclinical Alzheimer disease. Alzheimer Disease 
and Associated Disorders, 19(3), 163-165. doi: 00002093-200507000-00011 [pii] 
Mufson, E. J., Ma, S. Y., Cochran, E. J., Bennett, D. A., Beckett, L. A., Jaffar, S., . . . 
Kordower, J. H. (2000). Loss of nucleus basalis neurons containing trkA 
immunoreactivity in individuals with mild cognitive impairment and early 
Alzheimer's disease. Journal of Comparative Neurology, 427(1), 19-30.  
Nagahara, A. (2009). Neuroprotective effects of brain-derived neurotrophic factor in 
rodent and primate models of Alzheimer's disease. Nature medicine, 15(3), 331; 
331-337; 337. doi: 10.1038/nm.1912 pmid: 
Naylor, M. D., Karlawish, J. H., Arnold, S. E., Khachaturian, A. S., Khachaturian, Z. S., 
Lee, V. M.-Y., . . . Blennow, K. (2012). Advancing Alzheimer's disease 
diagnosis, treatment, and care: recommendations from the Ware Invitational 
Summit. Alzheimer's & Dementia, 8(5), 445-452.  
Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., & Brayne, C. (2014). Potential for 
primary prevention of Alzheimer's disease: an analysis of population-based data. 
Lancet Neurology, 13(8), 788-794. doi: 10.1016/S1474-4422(14)70136-X 
O'Brien, R. J., & Wong, P. C. (2011). Amyloid precursor protein processing and 
Alzheimer's disease. Annual Review of Neuroscience, 34, 185-204. doi: 
10.1146/annurev-neuro-061010-113613 [doi] 
Pagani, L., & Eckert, A. (2011). Amyloid-Beta interaction with mitochondria. 
International Journal of Alzheimer’s Disease, 2011.  
  70 
Park, R., Kook, S., Park, J., & Mook-Jung, I. (2014). Aβ1–42 reduces P-glycoprotein in 
the blood–brain barrier through RAGE–NF-κB signaling. Cell death & disease, 
5(6), e1299.  
Peng, S., Garzon, D. J., Marchese, M., Klein, W., Ginsberg, S. D., Francis, B. M., . . . 
Fahnestock, M. (2009). Decreased brain-derived neurotrophic factor depends on 
amyloid aggregation state in transgenic mouse models of Alzheimer's disease. The 
Journal of neuroscience, 29(29), 9321-9329.  
Peters, R., Poulter, R., Warner, J., Beckett, N., Burch, L., & Bulpitt, C. (2008). Smoking, 
dementia and cognitive decline in the elderly, a systematic review. BMC 
geriatrics, 8(1), 36.  
Pierrot, N., Ghisdal, P., Caumont, A. S., & Octave, J. N. (2004). Intraneuronal amyloid‐
β1‐42 production triggered by sustained increase of cytosolic calcium 
concentration induces neuronal death. Journal of neurochemistry, 88(5), 1140-
1150.  
Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001). 
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer 
disease. Archives of Neurology, 58(9), 1395-1402.  
Purves, D. (2001). Neuroscience. Sunderland, Mass: Sinauer Associates. 
Qosa, H., Abuznait, A. H., Hill, R. A., & Kaddoumi, A. (2012). Enhanced brain amyloid-
beta clearance by rifampicin and caffeine as a possible protective mechanism 
against Alzheimer's disease. Journal of Alzheimer's disease : JAD, 31(1), 151-
165. doi: 10.3233/JAD-2012-120319 [doi] 
Querfurth, H. (2010). Alzheimer's Disease. The New England journal of medicine, 
362(4), 329; 329-344; 344. doi: 10.1056/NEJMra0909142 pmid: 
Querfurth, H. W., & LaFerla, F. M. (2010). Alzheimer's disease. The New England 
journal of medicine, 362(4), 329-344. doi: 10.1056/NEJMra0909142 [doi] 
Reddy, P. H. (2011). Abnormal tau, mitochondrial dysfunction, impaired axonal transport 
of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain research, 
1415, 136-148.  
  71 
Reddy, P. H., & Beal, M. F. (2008). Amyloid beta, mitochondrial dysfunction and 
synaptic damage: implications for cognitive decline in aging and Alzheimer's 
disease. Trends in molecular medicine, 14(2), 45-53.  
Reddy, P. H., Manczak, M., Mao, P., Calkins, M. J., Reddy, A. P., & Shirendeb, U. 
(2010). Amyloid-β and mitochondria in aging and Alzheimer's disease: 
implications for synaptic damage and cognitive decline. Journal of Alzheimer's 
Disease, 20, 499-512.  
Roher, A. E., Esh, C. L., Kokjohn, T. A., Castaño, E. M., Van Vickle, G. D., Kalback, W. 
M., . . . Kuo, Y.-M. (2009). Amyloid beta peptides in human plasma and tissues 
and their significance for Alzheimer's disease. Alzheimer's & Dementia, 5(1), 18-
29.  
Roth, H. J., Schmidt-Gayk, H., Weber, H., & Niederau, C. (2008). Accuracy and clinical 
implications of seven 25-hydroxyvitamin D methods compared with liquid 
chromatography–tandem mass spectrometry as a reference. Annals of clinical 
biochemistry, 45(2), 153-159.  
Russ, T. C., & Morling, J. R. (2012). Cholinesterase inhibitors for mild cognitive 
impairment. The Cochrane Library.  
Saeki, M., Kurose, K., Tohkin, M., & Hasegawa, R. (2008). Identification of the 
functional vitamin D response elements in the human MDR1 gene. Biochemical 
pharmacology, 76(4), 531-542. doi: 10.1016/j.bcp.2008.05.030 [doi] 
Salva, A., Andrieu, S., Fernandez, E., Schiffrin, E., Moulin, J., Decarli, B., . . . Vellas, B. 
(2011). Health and nutrition promotion program for patients with dementia 
(NutriAlz): cluster randomized trial. The journal of nutrition, health & aging, 
15(10), 822-830.  
Scarmeas, N., Luchsinger, J. A., Schupf, N., Brickman, A. M., Cosentino, S., Tang, M. 
X., & Stern, Y. (2009). Physical activity, diet, and risk of Alzheimer disease. 
Jama, 302(6), 627-637.  
Scheff, S. (2007). Synaptic alterations in CA1 in mild Alzheimer disease and mild 
cognitive impairment. Neurology, 68(18), 1501; 1501-1508; 1508. doi: 
10.1212/01.wnl.0000260698.46517.8f pmid: 
  72 
Scheff, S. W., & Price, D. A. (2003). Synaptic pathology in Alzheimer’s disease: a 
review of ultrastructural studies. Neurobiology of aging, 24(8), 1029-1046.  
Scott, T. J., O'Connor, A. C., Link, A. N., & Beaulieu, T. J. (2014). Economic analysis of 
opportunities to accelerate Alzheimer's disease research and development. Annals 
of the New York Academy of Sciences, 1313, 17-34. doi: 10.1111/nyas.12417 [doi] 
Selkoe, D. J. (2004). Cell biology of protein misfolding: the examples of Alzheimer's and 
Parkinson's diseases. Nature cell biology, 6(11), 1054-1061.  
Shinto, L., Quinn, J., Montine, T., Dodge, H. H., Woodward, W., Baldauf-Wagner, S., . . 
. Silbert, L. (2014). A randomized placebo-controlled pilot trial of omega-3 fatty 
acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimer's 
Disease, 38(1), 111-120.  
Shipton, O. A., Leitz, J. R., Dworzak, J., Acton, C. E., Tunbridge, E. M., Denk, F., . . . 
Vargas-Caballero, M. (2011). Tau protein is required for amyloid {beta}-induced 
impairment of hippocampal long-term potentiation. The Journal of neuroscience : 
the official journal of the Society for Neuroscience, 31(5), 1688-1692. doi: 
10.1523/JNEUROSCI.2610-10.2011 [doi] 
Silverberg, G. D., Messier, A. A., Miller, M. C., Machan, J. T., Majmudar, S. S., Stopa, 
E. G., . . . Johanson, C. E. (2010). Amyloid efflux transporter expression at the 
blood-brain barrier declines in normal aging. Journal of neuropathology and 
experimental neurology, 69(10), 1034-1043. doi: 
10.1097/NEN.0b013e3181f46e25 [doi] 
Slinin, Y., Paudel, M., Taylor, B. C., Ishani, A., Rossom, R., Yaffe, K., . . . Ensrud, K. E. 
(2012). Association between serum 25 (OH) vitamin D and the risk of cognitive 
decline in older women. The Journals of Gerontology Series A: Biological 
Sciences and Medical Sciences, gls075.  
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., . . . Greengard, 
P. (2005). Regulation of NMDA receptor trafficking by amyloid-beta. Nature 
neuroscience, 8(8), 1051-1058. doi: nn1503 [pii] 
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., . . . 
Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer's 
disease: recommendations from the National Institute on Aging-Alzheimer's 
  73 
Association workgroups on diagnostic guidelines for Alzheimer's disease. 
Alzheimer's & dementia : the journal of the Alzheimer's Association, 7(3), 280-
292. doi: 10.1016/j.jalz.2011.03.003 [doi] 
Stewart, A. L., Mills, K. M., King, A. C., Haskell, W. L., Gillis, D., & Ritter, P. L. 
(2001). CHAMPS physical activity questionnaire for older adults: outcomes for 
interventions. Medicine & Science in Sports & Exercise(33), 1126-1141.  
Strauss, E., Sherman, E. M., & Spreen, O. (2006). A compendium of neuropsychological 
tests: Administration, norms, and commentary: Oxford University Press, USA. 
Supnet, C., & Bezprozvanny, I. (2010). Neuronal calcium signaling, mitochondrial 
dysfunction, and Alzheimer's disease. Journal of Alzheimer's disease : JAD, 20 
Suppl 2, S487-498. doi: 10.3233/JAD-2010-100306 [doi] 
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014). The Alzheimer's disease 
mitochondrial cascade hypothesis: progress and perspectives. Biochimica et 
Biophysica Acta (BBA)-Molecular Basis of Disease, 1842(8), 1219-1231.  
TakkoucheéI, B. (2006). A Meta-Analytic Study. Neuroepidemiology, 26, 226-232.  
Tampi, R. R., & van Dyck, C. H. (2007). Memantine: efficacy and safety in mild-to-
severe Alzheimer’s disease. Neuropsychiatric disease and treatment, 3(2), 245.  
Tangpricha, V. (2007). Vitamin D deficiency in the Southern United States. Southern 
medical journal, 100(4), 384.  
Toffanello, E. D., Coin, A., Perissinotto, E., Zambon, S., Sarti, S., Veronese, N., . . . 
Crepaldi, G. (2014). Vitamin D deficiency predicts cognitive decline in older men 
and women The Pro. VA Study. Neurology, 83(24), 2292-2298.  
Tripathi, M., & Vibha, D. (2009). Reversible dementias. Indian journal of psychiatry, 51 
Suppl 1, S52-55.  
Van Marum, R. J. (2008). Current and future therapy in Alzheimer’s disease. 
Fundamental & clinical pharmacology, 22(3), 265-274.  
  74 
Vasilevko, V., Xu, F., Previti, M. L., Van Nostrand, W. E., & Cribbs, D. H. (2007). 
Experimental investigation of antibody-mediated clearance mechanisms of 
amyloid-β in CNS of Tg-SwDI transgenic mice. The Journal of neuroscience, 
27(49), 13376-13383.  
Vedin, I., Cederholm, T., Freund-Levi, Y., Basun, H., Garlind, A., Irving, G. F., . . . 
Palmblad, J. (2012). Effects of DHA-rich n-3 fatty acid supplementation on gene 
expression in blood mononuclear leukocytes: the OmegAD study. PloS one, 7(4), 
e35425.  
Vigen, C. L., Mack, W. J., Keefe, R. S., Sano, M., Sultzer, D. L., Stroup, T. S., . . . 
Schneider, L. S. (2011). Cognitive effects of atypical antipsychotic medications in 
patients with Alzheimer's disease: outcomes from CATIE-AD. The American 
Journal of Psychiatry, 168(8), 831-839. doi: 10.1176/appi.ajp.2011.08121844 
[doi] 
Vogelgesang, S., Cascorbi, I., Schroeder, E., Pahnke, J., Kroemer, H. K., Siegmund, W., . 
. . Warzok, R. W. (2002). Deposition of Alzheimer's beta-amyloid is inversely 
correlated with P-glycoprotein expression in the brains of elderly non-demented 
humans. Pharmacogenetics, 12(7), 535-541.  
Wang, H. Y. (2000). beta -Amyloid1-42 Binds to alpha 7 Nicotinic Acetylcholine 
Receptor with High Affinity. IMPLICATIONS FOR ALZHEIMER'S DISEASE 
PATHOLOGY. The Journal of biological chemistry, 275(8), 5626; 5626-5632; 
5632. doi: 10.1074/jbc.275.8.5626 pmid: 
Wang, Q., Shah, N., Zhao, J., Wang, C., Zhao, C., Liu, L., . . . Zheng, J. (2011). 
Structural, morphological, and kinetic studies of beta-amyloid peptide aggregation 
on self-assembled monolayers. Physical chemistry chemical physics : PCCP, 
13(33), 15200-15210. doi: 10.1039/c1cp21156k [doi] 
Wang, Y. J., Zhou, H. D., & Zhou, X. F. (2006). Clearance of amyloid-beta in 
Alzheimer's disease: progress, problems and perspectives. Drug discovery today, 
11(19-20), 931-938. doi: S1359-6446(06)00309-6 [pii] 
Wijesuriya, H. C., Bullock, J. Y., Faull, R. L., Hladky, S. B., & Barrand, M. A. (2010). 
ABC efflux transporters in brain vasculature of Alzheimer's subjects. Brain 
research, 1358, 228-238. doi: 10.1016/j.brainres.2010.08.034 [doi] 
  75 
Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., & Landreth, G. E. (2013). 
Evidence for impaired amyloid beta clearance in Alzheimer's disease. Alzheimer's 
research & therapy, 5(4), 33. doi: 10.1186/alzrt187 [doi] 
Wilson, V. K., Houston Dk Fau - Kilpatrick, L., Kilpatrick L Fau - Lovato, J., Lovato J 
Fau - Yaffe, K., Yaffe K Fau - Cauley, J. A., Cauley Ja Fau - Harris, T. B., . . . 
Sink, K. M. (2014). Relationship between 25-hydroxyvitamin D and cognitive 
function in older adults: the Health, Aging and Body Composition Study. (1532-
5415 (Electronic)). doi: D - NLM: NIHMS558397 
D - NLM: PMC3989387 OTO - NOTNLM 
Wimo, A., Ballard, C., Brayne, C., Gauthier, S., Handels, R., Jones, R. W., . . . 
Kramberger, M. (2014). Health economic evaluation of treatments for 
Alzheimer's disease: impact of new diagnostic criteria. Journal of internal 
medicine, 275(3), 304-316. doi: 10.1111/joim.12167 [doi] 
Wimo, A., Jonsson, L., Bond, J., Prince, M., Winblad, B., & Alzheimer Disease, I. 
(2013). The worldwide economic impact of dementia 2010. Alzheimer's & 
dementia : the journal of the Alzheimer's Association, 9(1), 1-11.e13. doi: 
10.1016/j.jalz.2012.11.006 [doi] 
Woods, N. K., & Padmanabhan, J. (2012). Neuronal calcium signaling and Alzheimer's 
disease. Advances in Experimental Medicine and Biology, 740, 1193-1217. doi: 
10.1007/978-94-007-2888-2_54 [doi] 
Wurtman, R. (2014). Biomarkers in the diagnosis and management of Alzheimer’s 
disease. Metabolism.  
Xie, C. W. (2004). Calcium-regulated signaling pathways: role in amyloid beta-induced 
synaptic dysfunction. Neuromolecular Med, 6(1), 53-64. doi: 
10.1385/NMM:6:1:053 
Yan, R., & Vassar, R. (2014). Targeting the β secretase BACE1 for Alzheimer's disease 
therapy. The Lancet Neurology, 13(3), 319-329.  
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., . . . Price, D. 
(2003). Elevated β-secretase expression and enzymatic activity detected in 
sporadic Alzheimer disease. Nature medicine, 9(1), 3-4.  
  76 
Yang, T., Arslanova, D., Gu, Y., Augelli-Szafran, C., & Xia, W. (2008). Quantification 
of gamma-secretase modulation differentiates inhibitor compound selectivity 
between two substrates Notch and amyloid precursor protein. Molecular brain, 1, 
15-6606-6601-6615. doi: 10.1186/1756-6606-1-15 [doi] 
Yoon, S.-S., & Jo, S. A. (2012). Mechanisms of amyloid-β peptide clearance: potential 
therapeutic targets for Alzheimer’s disease. Biomolecules & therapeutics, 20(3), 
245.  
Zhang, S., Guo, Q., Edwards, H., Yates, P., & Li, C. (2014). Self-efficacy moderation 
and mediation roles on BPSD and social support influences on subjective 
caregiver burden in Chinese spouse caregivers of dementia patients. International 
psychogeriatrics / IPA, 1-9. doi: S1041610214000994 [pii] 
Zhang, W., Arteaga, J., Cashion, D. K., Chen, G., Gangadharmath, U., Gomez, L. F., . . . 
Liu, C. (2011). A highly selective and specific PET tracer for imaging of Tau 
pathologies. Journal of Alzheimer's disease: JAD, 31(3), 601-612.  
  77 
APPENDIX A 
IRB APPROVAL 
  78 
 
APPROVAL: MODIFICATION 
Carol Johnston 
SNHP - Nutrition 
602/827-2265 
CAROL.JOHNSTON@asu.edu 
Dear Carol Johnston: 
On 2/27/2015 the ASU IRB reviewed the following protocol: 
Type of Review: Modification 
Title: The Effect of Vitamin D Supplementation on Plasma 
Aβ in an Elderly Population: A Randomized Control 
Trial 
Investigator: Carol Johnston 
IRB ID: STUDY00001924 
Funding: None 
Grant Title: None 
Grant ID: None 
Documents Reviewed: • Dietary vitamin D questionnaire, Category: 
Measures (Survey questions/Interview questions 
/interview guides/focus group questions); 
• consent - modified, Category: Consent Form; 
• protocol , Category: IRB Protocol; 
• Friendship Village email, Category: Off-site 
authorizations (school permission, other IRB 
approvals, Tribal permission etc); 
• Physical activity questionnaire, Category: 
Screening forms; 
• Health history, Category: Screening forms; 
• research ad, Category: Recruitment Materials; 
• MMSE, Category: Screening forms; 
 
The IRB approved the modification.  
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When consent is appropriate, you must use final, watermarked versions available under 
the “Documents” tab in ERA-IRB. 
In conducting this protocol you are required to follow the requirements listed in the 
INVESTIGATOR MANUAL (HRP-103). 
Sincerely, 
IRB Administrator 
cc:  
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1. Please provide your primary email address (if applicable): 
_________________________________________ 
 
2. Please provide your phone number. 
_________________________________________ 
 
2. What is your preferred way of communication? 
 
Email OR Phone 
 
3. Are you 50 years of age or older?  Yes  No 
 
5. Are you consuming any medications? Yes  No 
 
6. If you answered yes to the above question, list medications currently using: 
_________________________________________ 
_________________________________________ 
_________________________________________ 
_________________________________________ 
_________________________________________ 
 
 
7. Are you taking any nutritional supplements?  Yes  No 
 
8. If you answered yes to the above question, list nutritional supplements currently 
using: 
_________________________________________ 
_________________________________________ 
_________________________________________ 
_________________________________________ 
_________________________________________ 
 
9. Has your physician diagnosed you with any form of dementia?    
 
Yes  No 
 
10. Has your physician diagnosed you, currently, with high cholesterol? 
 
Yes  No 
 
11. Has your physician diagnosed you, currently, with diabetes?  
 
Yes  No 
 
12. Has your physician diagnosed you with kidney disease? 
  82 
 
Yes  No 
 
13. Has your physician diagnosed you with liver disease? 
 
Yes  No 
 
14. Would you be willing to visit with ASU investigators at Friendship Village, 
Beatitudes, or the downtown Phoenix ASU lab three times within a 8 week span? 
 
Yes  No 
 
15. Are you ok with providing a blood sample from the arm vein? (a trained 
phlebotomist will perform the blood draw) 
 
Yes  No 
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HEALTH HISTORY QUESTIONNAIRE                                ID#___________________ 
1. Gender:  M    F 
 
2. To be filled in by investigator: Body weight ____________ Height _________ 
 
3.  Age:  __________ 
 
4. Ethnicity: (please circle)  Native American     African-American     Caucasian     
Hispanic     Asian     Other 
 
5. Have you been treated by a physician for high cholesterol?    Yes    No 
     If yes please explain: 
______________________________________________________________________ 
 
6. Have you lost or gained a significant amount of weight in the last 12 months?         Yes         
No 
     If yes, how much lost or gained? _________     How long ago? ___________ 
 
7.  Have you been diagnosed with diabetes?                                                                   
Yes       No          
 
8. Have you been diagnosed with kidney disease or liver disease?                                
Yes         No  
 
9. Do you currently take any medications?                                                                     
Yes          No          
 
If yes, please list type and frequency: 
 
Medication    Dosage    Frequency 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
________________________________________________________________________
________________________________________________________________________
____________________________________ 
 
 
10. Have you take vitamin D supplements in the past 2 years?                                          
Yes        No 
 
  89 
11.  Have you ever been told by a doctor that you are low in vitamin D?                         
Yes       No 
 
12.  Do you currently take any other supplements (vitamins, minerals, herbs, etc.) ?        
Yes    No          
 
If yes, list type and frequency:                               
Supplement    Dosage    Frequency 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________  
 
 
13.  Have you been hospitalized within the last 2 years?     Yes   No 
 
If yes, please explain:   
 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________  
 
 
14.  Have you been diagnosed with any form of autoimmune disease (e.g., Chron’s, 
Celiac’s, etc.)?   Yes       No 
 
15.  Do you get nervous or faint when blood is drawn from an arm vein?                                             
Yes      No 
 
16.  Will you have any concerns consuming a large gel capsule?  (once weekly)                                  
Yes      No 
 
17.  Are there any other health-related issues you need to tell us before starting this trial?        
Yes         No 
 
If yes, please explain:   
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
______________________________________________________ 
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Title of research study: Vitamin D supplementation for clearing amyloid proteins from 
the brain in senior citizens: a randomized controlled trial  
Investigators: Carol Johnston, ASU Nutrition Professor; Brendan Miller, Nutrition 
Master’s student  
Why am I being invited to take part in a research study? 
We invite you to take part in this research study because you are a healthy adult over the 
age of 50 with a vitamin D insufficiency and without diabetes, kidney disease, liver 
disease, or conditions that would affect platelet levels.  
Why is this research being done? 
The purpose of this research is to examine the effect of vitamin D on clearing harmful 
proteins out of the brain. There are a growing number of people who are developing 
Alzheimer’s disease because of a buildup of amyloid proteins in the brain. Identifying 
factors that might contribute to progression of this disease is important because the 
number of Alzheimer’s disease cases is expected to exponentially increase in the next 
decade.  
How long will the research last? 
We expect individuals to spend 8 weeks participating in the proposed activities. 
How many people will be studied? 
We expect about 40 people will participate in this research study. 
What happens if I say yes, I want to be in this research? 
You will be a participant in this study for approximately 8 weeks. Your participation 
includes three visits: one for initial screening and blood draw, the second for dispersion 
of supplement and instructions, and third for your final blood draw. You will only need to 
have your blood drawn twice: once at the beginning of the study and once at the end of 
the 8-week supplementation period. Approximately 2 tablespoons of blood will be 
collected at each blood draw. Your first visit will be a screening to evaluate vitamin D 
levels in the blood and memory. If you qualify and are fasting, your blood will be drawn 
at that time; or if you are not fasting, this visit will be rescheduled. At the second visit, 
you will be given either a vitamin D supplement or placebo to consume once a week for 8 
weeks. In addition to instructions, you will be given a compliance calendar to note what 
day of the week the supplement was consumed and will be asked questions related to 
physical activity and diet. The day you consume the supplement will be the same day 
every week (e.g., once on Monday every week). The length of each visit will 
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approximately last 15-20 minutes. During the research process, you will interact with the 
research team, consisting of the investigator, a registered nurse, and a lab technician. The 
contact information of the investigators will be provided to you. The processing of the 
blood sample will be done at the Arizona Biomedical Collaborative laboratory (ABC) in 
downtown Phoenix. The research team is testing for the molecules of beta amyloid from 
your blood sample. There are two groups in this research trial. One group will be given a 
vitamin D supplement, whereas the other group will be given a placebo. You will not 
know which group you fall into, nor will the investigator. The research trial is expected to 
last from April 2015-May 2015.  
What happens if I say yes, but I change my mind later? 
You can leave the research at any time it will not be held against you. If you decide to 
leave the research, there will be no adverse consequences. If you decide to leave the 
research, contact the investigator so that the investigator can appropriately exclude you 
from the trial.  
Is there any way being in this study could be bad for me? 
While taking the vitamin D supplement is likely safe in the prescribed amounts (1 
capsule, 1 time per week for 8 weeks), there are potential physical risks associated with 
consuming the vitamin D supplement in toxic amounts. If you accidentally consume too 
many capsules, calcium levels in your blood may rise. This calcium rise can leave you 
feeling weak, nauseated, with a headache, and at a risk for kidney stones.  You may feel 
temporarily nauseous or faint during the blood draw.  Blood draws are performed by a 
registered nurse or a trained phlebotomist who are experienced in handling these issues.  
Taking part in this research study may lead to added costs and time commitments.  
Driving to the ASU nutrition laboratory in Phoenix will entail gas costs, and you may 
need to pay the meter for curbside parking (costs should be < 50 cents).  
Will being in this study help me any way? 
We cannot promise any benefits to you or others from your taking part in this research. 
However, your participation will help the scientists advance knowledge regarding 
vitamin D and Alzheimer’s disease.  
 What happens to the information collected for the research? 
Efforts will be made to limit the use and disclosure of your personal information, 
including research study data, to people who have a need to review this information. We 
cannot promise complete secrecy. Organizations that may inspect and copy your 
information include the Institutional Review Board at Arizona State University and other 
representatives of this organization. All data and blood samples collected during this 
study will be identified only by a number assigned to you and stored in a secure setting in 
the ABC laboratory. 
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What else do I need to know? 
If you agree to participate in the study, written consent does not waive any of your legal 
rights. However, no funds have been set aside to compensate you in the event of injury.  
Who can I talk to? 
If you have questions, concerns, or complaints, or think the research has hurt you, talk to 
the research team at Arizona State University. You may email or call the investigators 
[Carol.Johnston@asu.edu (602)827-2265 or Brendan.Miller@asu.edu (480)580-0099] to 
express any concerns.  
This research has been reviewed and approved by the Bioscience Institutional Review 
Board at ASU. You may talk to them at (480) 965-6788 or research.integrity@asu.edu if: 
• Your questions, concerns, or complaints are not being answered by the research 
team. 
• You cannot reach the research team. 
• You want to talk to someone besides the research team. 
• You have questions about your rights as a research participant. 
You want to get information or provide input about this research. 
Your signature documents your permission to take part in this research. 
 
 
Signature of participant                              Date 
                         
                   Email or phone# 
 
Printed name of participant                            
   Signature of person obtaining consent                               Date 
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MINI-MENTAL STATE EXAMINATION 
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ID#: ___________________  
 
Right / Wrong?  - 30 questions for 30 points  
ORIENTATION – 10 points 
Ask the following questions: 
1. What is today's date? 
2. What is the month? 
3. What is the year? 
4. What day of the week is it today? 
5. What season is it?                                              
6. What is the name of this clinic (place)? 
7. What floor are we on? 
8. What city are we in?  
9. What county are we in? 
10. What country are we in?                          Orientation subtotal =    /10 
 
IMMEDIATE RECALL – 3 points 
Ask the subject if you may test his/her memory. Then say "ball", "flag", "tree" clearly and slowly, 
about 1 second for each. After you have said all 3 words, ask him/her to repeat them - the first 
repetition determines the score (0-3):  
11. BALL 
12. FLAG 
13. TREE                                                   Recall subtotal =     /3 
 
ATTENTION – 5 points 
NB PERFORM SERIAL 7S OR ‘WORLD’ BACKWARDS BUT NOT BOTH! 
 
A) Ask the subject to begin with 100 and count backwards by 7. Stop after 5 subtractions. Score 
the correct subtractions. 
14. "93" 
15. "86" 
16. "79" 
17. "72" 
18. "65"                                               
 
B) Ask the subject to spell the word "WORLD" backwards. The score is the number of letters in 
correct position. For example, "DLROW" is 5, "DLORW" is 3, "LROWD" is 0. 
"D" 
"L" 
"R" 
"O" 
"W"                                             "DLROW" or Serial 7s subtotal =         /5     
 
DELAYED VERBAL RECALL – 3 points 
Ask the subject to recall the 3 words you previously asked him/her to remember.  
19. BALL? 
20. FLAG? 
21. TREE?                                  Delayed verbal recall subtotal =          /3 
 
NAMING –2 points  
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Show the subject a wrist watch and ask him/her what it is. Repeat for pencil.  
22. WATCH 
23. PENCIL 
 
REPETITION – 1 point 
Ask the subject to repeat the following :"No ifs, ands, or buts"  
25. REPETITION 
 
3-STAGE COMMAND - 3 points 
Give the subject a plain piece of paper and say, "Take the paper in your hand, fold it in half, and 
put it on the floor."  
25. TAKES 
26. FOLDS 
27. PUTS 
 
READING – 1 point 
Hold up the card reading, "Close your eyes", so the subject can see it clearly. Ask him/her to read 
it and do what it says. Score correctly only if the subject actually closes his/her eyes. 
28. CLOSES EYES 
 
WRITING 1 point 
Give subject a piece of paper and ask him/her to write a sentence. It is to be written 
spontaneously. It must contain a subject and verb and be sensible. Correct grammar and 
punctuation are not necessary.  
29. SENTENCE 
                                              Language subtotal = /8  
            
COPYING – 1 point 
Give subject a piece of paper and ask him/he to copy a design of two intersecting shapes. One 
point is awarded for correctly copying it. All angles on both figures must be present, and the 
figures must have one overlapping angle.  
Example:  
 
30. PENTAGONS                                    Pentagon subtotal  =           /1 
 
 TOTAL MMSE =            /30 
(MMSE maximum score =
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CHAMPS Activities Questionnaire for 
Older Adults 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAMPS: Community Healthy Activities Model Program for Seniors 
Institute for Health & Aging, University of California San Francisco  
Stanford Center for Research in Disease Prevention, Stanford University 
 (11/06/00) © Copyright 1998  
 Do not reproduce without permission of the CHAMPS staff 
Contact: Anita L. Stewart, Ph.D., UCSF, anitast@itsa.ucsf.edu  
 
Date:_________________________________ 
 
Name or ID:___________________________ 
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This questionnaire is about activities that you may have done in the past 4 weeks.  
The questions on the following pages are similar to the example shown below. 
INSTRUCTIONS 
 
If you DID the activity in the past 4 weeks: 
Step #1 Check the YES box.  
Step #2 Think about how many TIMES a week you usually 
did it, and write your response in the  
space provided. 
Step #3 Circle how many TOTAL HOURS in a typical week 
you did the activity.  
 
Here is an example of how Mrs. Jones would answer 
question #1:  Mrs. Jones usually visits her friends Maria and 
Olga twice a week.  She usually spends one hour on Monday with 
Maria and two hours on Wednesday with Olga.  Therefore, the total 
hours a week that she visits with friends is 3 hours a week. 
 
In a typical week 
during the past 4 
weeks, did you… 
       
 
1. Visit with friends or 
family (other than those 
you live with)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
1. Visit with friends or 
family (other than those 
you live with)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
   
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
4. Go to the senior 
center? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
3. Do volunteer work?  
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
4. Attend church or take 
part in church activities? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
5. Attend other club or 
group meetings? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
6. Use a computer? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
7. Dance (such as 
square, folk, line, 
ballroom) (do not count 
aerobic dance here)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
8. Do woodworking, 
needlework, drawing, or 
other arts or crafts? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
9. Play golf, carrying or 
pulling your equipment 
(count walking time 
only)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
10. Play golf, riding a 
cart (count walking time 
only)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
11. Attend a concert, 
movie, lecture, or sport 
event? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
12. Play cards, bingo, or 
board 
games with other 
people? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
13. Shoot pool or 
billiards? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
14. Play singles tennis 
(do not count doubles)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
15. Play doubles tennis 
(do not count singles)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
16. Skate (ice, roller, in-
line)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
17. Play a musical 
instrument? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
18. Read? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
19. Do heavy work 
around the house (such 
as washing windows, 
cleaning gutters)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
20. Do light work around 
the house (such as 
sweeping or 
vacuuming)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
21. Do heavy gardening 
(such as spading, 
raking)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
22. Do light gardening 
(such as watering 
plants)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
23. Work on your car, 
truck, lawn mower, or 
other machinery? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
**Please note:  For the following questions about running and walking, 
include use of a treadmill. 
 
24. Jog or run? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
  108 
In a typical week 
during the past  
4 weeks, did you … 
       
 
25. Walk uphill or hike 
uphill (count only uphill 
part)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
26. Walk fast or briskly 
for exercise (do not 
count walking leisurely 
or uphill)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
27. Walk to do errands 
(such as to/from a store 
or to take children to 
school (count walk time 
only)?  
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
28. Walk leisurely for 
exercise or pleasure? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
29. Ride a bicycle or 
stationary cycle? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
30. Do other aerobic 
machines such as 
rowing, or step machines 
(do not count treadmill 
or stationary cycle)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
31. Do water exercises 
(do not count other 
swimming)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
32. Swim moderately or 
fast? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
33. Swim gently? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
34. Do stretching or 
flexibility exercises (do 
not count yoga or Tai-
chi)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
35. Do yoga or Tai-chi? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
36. Do aerobics or 
aerobic dancing? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
37. Do moderate to 
heavy strength training 
(such as hand-held 
weights of more than 5 
lbs., weight machines, or 
push-ups)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
38. Do light strength 
training (such as hand-
held weights of 5 lbs. or 
less or elastic bands)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
39. Do general 
conditioning exercises, 
such as light calisthenics 
or chair exercises (do not 
count strength training)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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In a typical week 
during the past  
4 weeks, did you … 
       
 
40. Play basketball, 
soccer, or racquetball 
(do not count time on 
sidelines)? 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
 
41. Do other types of 
physical activity not 
previously mentioned  
(please specify)? 
 
__________________ 
 NO      
 YES   How many  
TIMES a week?_____ 
! 
 
How 
many 
TOTAL 
hours a 
week 
did you 
usually 
do it? 
! 
Less 
than  
1 
hour 
 
1-2½ 
hours 
 
3-4½ 
hours 
 
5-6½ 
hours 
 
7-8½ 
hours 
9 or 
more 
hours 
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APPENDIX I  
BRIEF VITAMIN D QUESTIONNAIRE 
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Food day  OR week  OR month 
Medium Serving 
Size S M L 
Milk, liquid all types       1 cup       
Milk, dry powder       1 Tbs       
Milk in coffee/tea       1 Tbs       
Cheese, cheddar       1 oz       
Cheese, parmesan       1 oz       
Cheese, swiss       1 oz       
Egg custard, pudding       1 cup       
Yogurt drink.  
Brand____________       11 oz       
Yogurt. Brand 
________________       4 oz       
Ice cream       1/2 cup       
Egg, whole or yolk (17g)       1 each       
Beef (lean cuts)       3 oz       
Hamburger/Cheeseburger       3 oz       
Hot dog (beef or pork)       1 dog       
Salami       3 slices       
Bologna       1 ounce       
Whitefish (cod, flounder)       3 oz       
Herring (Atlantic)       3 oz raw       
Herring (pickled)       3 oz       
Tuna (canned in oil)       3 oz       
Mackerel (Atlantic, Pacific, 
canned)       1 cup       
Oysters Eastern wild       6 medium raw       
Chum canned salmon       3 oz       
Salmon pink, canned       3 oz       
Sardines, canned in 
tomato sauce       1 sardine       
Sardines canned in oil       2 sardines       
Shrimp       3 oz raw       
Butter/Margarine       1 pat       
Cream       1 Tbs       
Cod Liver Oil       1 Tbs       
Mushrooms, raw       1/2 cup       
Mushroom, Shiitake, dried       1 each       
Orange juice, fortified with 
Vitamin D (MinMaid)       8 oz       
All kinds, fortified. 
Cereal________________       1 cup       
Rice Beverage Enriched       1 cup       
Soy milk enriched.  
Brand_____________       1 cup       
Salmon unspecified filet       3 oz       
 
  
  116 
APPENDIX J  
AMYLOID BETA 40 ELISA KIT, HUMAN PROTOCOL  
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Preparing Standard Reconstitution Buffer 
Dissolve 2.31 grams of sodium bicarbonate in 500 mL of deionized water. Add 2 
N sodium hydroxide until pH is 9.0. Filter solution through a 0.2 µm filter unit.  
Note: This buffer is used to reconstitute the lyophilized standard. Do not use this 
buffer to dilute the standard or samples. 
 
Dilution of Standard 
Note: Polypropylene tubes may be used for standard dilutions. 
 
The Hu Aβ40 Standard is calibrated against highly purified Hu Aβ where 
mass was corrected for peptide content by amino acid analysis. 
 
1. Remove the Hu Aβ40 Standard vial from storage and let equilibrate to room 
temperature (RT).  
2. Reconstitute standard to 100 ng/mL with Standard Reconstitution Buffer (55 
mM sodium bicarbonate, pH 9.0). Refer to the standard vial label for 
instructions. Swirl or mix gently and allow to sit for 10 minutes to ensure 
complete reconstitution. Briefly vortex prior to preparing standard curve.   
3. Generation of the standard curve using the Aβ peptide standard must be 
performed using the same composition of buffers used for the diluted 
experimental samples. For example, if brain extracts are diluted 1:10 with   
Standard Diluent Buffer, then the buffer used to dilute standards should be 
90% Standard Diluent Buffer and 10% brain extraction buffer (including 
AEBSF at a final concentration of 1 mM).   
4. Add 0.1 mL of the reconstituted standard to a tube containing 0.9 mL of the 
Standard Diluent Buffer. Label as 10,000 pg/mL Hu Aβ40. Mix.   
5. Add 0.1 mL of the 10,000 pg/mL standard to a tube containing 1.9 mL  
Standard Diluent Buffer. Label as 500 pg/mL Hu Aβ40. Mix.  
6. Add 0.15 mL of Standard Diluent Buffer to each of 6 tubes labeled 250, 125, 
62.5, 31.25, 15.63, 7.81, and 0 pg/mL Hu Aβ40.   
7. Make serial dilutions of the standard as described in the following dilution 
diagram. Mix thoroughly between steps.  
 
Note: Remaining reconstituted Hu A β40 standard may be stored in aliquots at -
80°C for up to 4 months. Standard can be frozen and thawed one time only 
without loss of immunoreactivity. 
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Preparing Secondary Antibody  
Note: Prepare within 15 minutes of usage. The Anti-Rabbit IgG HRP (100X) is 
in 50% glycerol, which is viscous. To ensure accurate dilution, allow Anti-Rabbit 
IgG HRP (100X) to reach room temperature. Gently mix. Pipette Anti-Rabbit IgG 
HRP (100X) slowly. Remove excess concentrate solution from pipette tip by 
gently wiping with clean absorbent paper. 
1. Dilute 10 µL of this 100X concentrated solution with 1 mL 
of HRP Diluent for each 8-well strip used in the assay. 
Label as Anti-Rabbit IgG HRP Working Solution.   
2. Return the unused Anti-Rabbit IgG HRP (100X) to the 
refrigerator.   
 
# of 8-Well Strips 
Volume of Anti-Rabbit IgG 
HRP 
Volume of Diluent   (100X)      
 
 2 20 µL solution 2 mL 
 
 4 40 µL solution 4 mL 
 
 6 60 µL solution 6 mL 
 
 8 80 µL solution 8 mL 
 
 10 100 µL solution 10 mL 
 
 12 120 µL solution 12 mL 
 
 
Sample Preparation 
Prepare one or more dilutions of each sample. These dilutions should be made in  
Standard Diluent Buffer, although the exact dilution must be determined 
empirically (e.g., 1:2 and 1:10 represent a reasonable range). This dilution must 
be performed because certain components in samples can interfere with the 
detection of the Aβ peptides or to bring the levels of Aβ within the range of this 
assay. AEBSF should be added to the diluted samples and the standards at a 
final concentration of 1 mM in order to prevent proteolysis of the Aβ peptides.  
Refer to β-Amyloid Application (page 13) for procedure for homogenization of 
human or transgenic mouse brains.  
Note: Analysis of plasma samples may require pretreatment to disrupt interaction 
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of Aβ with masking proteins. 
 
Assay Procedure 
Be sure to read the Procedural Notes section before carrying out the assay.  
Allow all reagents to reach room temperature before use. Gently mix all liquid 
reagents prior to use.  
Note: A standard curve must be run with each assay.  
1. Determine the number of 8-well strips needed for the assay. Insert these in 
the frame(s) for current use. (Re-bag extra strips and frame. Store these in 
the refrigerator for future use.)   
2. Add 50 µL of the Standard Diluent Buffer to the zero standard wells. Well(s) 
reserved for chromogen blank should be left empty.  
3. Prepare samples and standards with appropriate diluents. Add 50 µL of Aβ 
peptide standards, controls, and samples to each well except for the 
chromogen blank (s).  
4. Add 50 µL of Hu Aβ40 Detection Antibody solution to each well except for 
the chromogen blank(s).  
5. Cover plate with plate cover and incubate for 3 hours at room temperature 
with shaking.  
6. Thoroughly aspirate or decant solution from wells and discard the liquid.  
Wash wells 4 times. See Directions for Washing.  
7. Add 100 µL Anti-Rabbit IgG HRP Working Solution to each well except the 
chromogen blank(s). See Preparation of Reagents.  
8. Cover plate with the plate cover and incubate for 30 minutes at room 
temperature.  
9. Thoroughly aspirate or decant solution from wells and discard the liquid.  
Wash wells 4 times. See Directions for Washing.  
10. Add 100 µL of Stabilized Chromogen to each well. The liquid in the wells will 
begin to turn blue.   
11. Incubate for 30 minutes at room temperature and in the dark.   
Note: Do not cover the plate with aluminum foil or metalized mylar. The 
incubation time for chromogen substrate is often determined by the 
microtiter plate reader used. Many plate readers have the capacity to record 
a maximum optical density (O.D.) of 2.0. The O.D. values should be 
monitored and the substrate reaction stopped before the O.D. of the positive 
wells exceeds the limits of the instrument. The O.D. values at 450 nm can 
only be read after the Stop Solution has been added to each well. If using a 
reader that records only to 2.0 O.D., stopping the assay after 15 to 20 
minutes is suggested.   
12. Add 100 µL of Stop Solution to each well. Tap side of plate gently to mix.  
The solution in the wells should change from blue to yellow.  
13. Read the absorbance of each well at 450 nm having blanked the plate 
reader against a chromogen blank composed of 100 µL each of Stabilized   
Chromogen and Stop Solution. Read the plate within 30 minutes after 
adding the Stop Solution.   
14. Use a curve fitting software to generate the standard curve. A four 
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parameter algorithm provides the best standard curve fit.   
15. Read the concentrations for unknown samples and controls from the 
standard curve. Multiply value(s) obtained for sample(s) by the 
appropriate factor to correct for the sample dilution. (Samples 
producing signals greater than that of the highest standard should be further 
diluted in Standard Diluent Buffer and reanalyzed, multiplying the 
concentration found by the appropriate dilution factor.)  
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APPENDIX K  
ORIGINAL BASELINE DESCRIPTIVE STATISTICS (N=23) 
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Table 4 
   Original baseline descriptive statistics (n=23)a 
Characteristics Vitamin D group Control Group p value 
  n=12 n=11   
Baseline values   
 Male 3 3 
 Female 9 8 
 Age 64.3 + 3.0 64.5 + 3.6 0.975 
BMI 25.2 + 1.1 26.7 + 1.9 0.489 
aAll values are means + SE 	  	   	  	   	  	  
 
